Patent Application
20240318134
The invention relates to in vitro generation of organized 3D cell structures recapitulating various degrees of early organogenesis, including head-trunk embryo-like structures, using epigenetic remodeling factors. The invention relates in particular to methods of obtaining such organized 3D cell structures from mammalian cells, in particular non-human mammalian cells and to devices, in particular microfluidic platform, to perform such methods.
The invention also concerns the use of the thus obtained 3D cell structures in applications of molecule screening, developmental testing, production of physiologically active substances and models for therapeutic investigation or use.
In vitro recapitulation of early mammalian embryogenesis is a very active field of research1-13. Two main strategies have been developed to build mouse or human embryo-like structures (ELS), either by combining embryonic and extraembryonic stem cells1-3, which spontaneously self-organize to mimic post-implantation embryos, or by challenging embryonic stem cells (ESCs) with a pulse of Wingless-type integration site protein (WNT) agonist to recapitulate early organogenesis4-8. However, a large portion of the central nervous system is missing from these structures, particularly brain derivatives.
By contrast, the inventors have been able to design methods suitable to prepare 3D cell structures that may enable to obtain various degrees of early organogenesis, until elongated ELS characterized by a head-to-tail body axis with mid-hindbrain neuronal cell types as well as Schwann cell precursors, concomitant with somitogenesis.
The inventors have also shown that morphogen-free protocols can be designed in order to prepare organized 3D cell structures and the designed methods provide a step forward in exploring neural networks in embryos, showing that in vitro multicellular self-organization recapitulating early developmental organogenesis can be achieved using epigenetic remodeling factors. Among epigenetic remodeling factors, the inventors have addressed the effects of modulating the small ubiquitin-like modifier (SUMO) signaling pathway on pluripotent or multipotent vertebrates cell fate, in particular mammalian cell fate.
As is known in the art, the dynamic post-translational modification by small ubiquitin-like modifier (SUMO) predominantly targets chromatin-associated proteins14-18, granting SUMOylation the ability to broadly affect the chromatin landscape, and modulate large transcriptional programs17-20. Recently, SUMO has been implicated in safeguarding cell fate, both in vivo and in vitro, by stabilizing substrate complexes on key cell identity genes21-25. Notably, suppressing SUMOylation is sufficient to promote conversion of mouse ESCs to two-cell-stage-like (2C-L) cells23. The inventors hypothesized that sequential waves of hypoSUMOylation in ESCs would further expand cell diversity.
The methods of the invention stem from the determination by the inventors that repeated transient inhibition of small ubiquitin-like modifier (SUMO) conjugation (so-called hypoSUMOylation) in mouse ESCs was suitable and sufficient to form organized 3D cell structures encompassing characterized epiblast-containing spheroids. These epiblast-like cells of spheroids were then capable of undergoing lineage-specific differentiation into all three embryonic germ layers when cultured in different culture formats including 2D plates or 3D microfluidics, especially in an optimized droplet-microfluidic platform. Mechanistically, the steps (i.e. rounds) of hypoSUMOylation gradually increased the global level of DNA methylation, which in turn repressed transcription of Nanog and other pluripotency-associated genes, facilitating cell fate determination.
The invention accordingly relates to methods of in vitro preparing organized 3D cell structures of vertebrate cells, advantageously mammalian cells wherein the organized 3D cell structures achieve various levels of early-stage developmental events of mammalian embryos, in particular development stages taking place during gastrulation or early organogenesis. In an aspect of the invention, the prepared organized 3D cell structures recapitulate development until a spheroid structure is obtained. In an aspect of the invention, the prepared organized 3D cell structures recapitulate development until a gastruloid structure is obtained. In another particular aspect of the invention, diversification of cell types recapitulates early organogenesis.
In a further aspect the invention relates to a specific microfluidic platform, including a device which has been uniquely designed for pluripotent stem cells culture. This device and format of culture have proved to promote the generation of the organized 3D cell structures. Beside reducing the volume of culture, the microfluidic platform of the invention provides a unique complex microenvironment generated by a controlled level of biochemical and mechanical confinement (due to accumulation of secreted molecules and unique cell/interface interactions), e.g. for the generation of late gastruloids and embryoids. These microenvironmental conditions may be also favorable for the maturation of other type of organoids derived from pluripotent stem cells (PSCs).
In a particular aspect, the invention relates to methods of in vitro preparing organized 3D cell structures of non-human mammalian cells, in particular rodents, especially mice, in particular laboratory mammalian animals. In a particular aspect, the invention relates to methods of in vitro preparing organized 3D cell structures of mammalian cells that are human cells.
The invention accordingly relates to a method of in vitro preparing organized 3D cell structures of mammalian cells wherein the method comprises:
In a particular embodiment, the method is carried out when in step i. a homogeneous population of pluripotent or multipotent cells is provided. In an embodiment, the method is carried out when in step i. a homogeneous population of pluripotent or multipotent non-human mammalian cells, especially non-human embryonic stem cells is provided. In an embodiment, the method is carried out when in step i. a homogeneous population of pluripotent or multipotent human mammalian cells, especially human embryonic stem cells is provided. In a particular embodiment the second culture medium as defined in step iii. above is a single second culture medium as defined herein.
The expression “organized 3D cell structure” relates to cells that self-organize as 3D aggregates and recapitulate early development stages of animal tissues. Developmental stages may include differentiation and maturation of the pluripotent or multipotent cells provided to perform the methods of the invention. The organized 3D cell structures reflect dynamic spatiotemporal development in vitro of the originally provided population of pluripotent or multipotent cells while performing the methods of the invention. In a particular embodiment, the cell population initially provided is a homogenous population of cells such as a single population of pluripotent or multipotent cells while performing the methods of the invention. The term «homogenous» has the common meaning in the art and especially refers to a population of cells having similarities in their proliferation (also disclosed as division progression or self-renewal capacity) and differentiation outcome. The organized 3D cell structures in particular exhibit multiple cell types providing cell clusters that may be organized as discrete layers, in particular multiple germ layers. A cell cluster is a set of cells sharing a similar transcriptomic profile and that may be detected together in scRNA seq analysis. The organized 3D cell structure may be said to be self-assembled. The expression “self-assembled” as disclosed herein relates to how the organized 3D cell structure is made when carrying out the methods of the invention.
According to various embodiments of the invention, organized 3D cell structures according to the invention may accordingly have achieved various stages of development and may be recovered as spheroids, or as polarized structures showing anterior-posterior polarization, or elongated axed structures such as anterior-posterior body axed structures (also designated as head-to-tail body axis), including in particular elongating-multilineages-organized (EMLO) structures such as gastruloids or embryoids. According to a particular embodiment, these organized 3D cell structures are non-human mammalian structures. According to a particular embodiment, these organized 3D cell structures are 3D structures of human cells. According to a particular embodiment, these organized 3D cell structures have been obtained without the use of embryo. According to a particular embodiment, these organized 3D cell structures lack cell totipotency or cell pluripotency. According to a particular embodiment, these organized 3D cell structures lack certain types of cells such as 2C-like cells. According to an embodiment, when the organized 3D cell structures are gastruloids according to the invention, they lack Primordial Germ Cells and/or trophectoderm. According to an embodiment, when the organized 3D cell structures are embryoids according to the invention, they lack at least one of the following types of cells: notochord, forebrain, sclerotome, floor plate organizer, extra-embryonic annexes, blood cells and/or allantois.
The expressions “pluripotent cells” or “multipotent cells” relate to unspecialized cells with self-renewal capacity and potential to differentiate as all cell types of the body (pluripotent cells) or as multiple cell types of the body (multipotent cells). Examples of such cells are Embryonic Stem Cells (ESC) or Adult Stem Cells. The expression “homogenous population of pluripotent or multipotent cells” relates to such cells originating essentially from a single source. In a particular embodiment, the term «homogenous» has the common meaning in the art and refers to a population of cells having similarities in their proliferation (also disclosed as division progression or self-renewal capacity) and differentiation outcome
The population of pluripotent or multipotent cells or the homogeneous population of pluripotent or multipotent cells may accordingly be Embryonic stem cells, in particular mammalian embryonic stem cells. In a particular embodiment, the ESCs are non-human mammalian embryonic stem cells, for example rodent embryonic stem cells such as mouse or rat embryonic stem cells. Alternatively, the homogeneous population of pluripotent or multipotent cells may be induced pluripotent stem cells (iPSC). In a particular embodiment, when the starting population of cells is human cells, the cells are induced pluripotent stem cells (iPSC). In a particular embodiment, the ESCs or the PSCs are human ESCs. In a particular embodiment, when a human embryo is used to provide human ESCs, the method for obtaining ESCs from the embryo does not comprise destructing the embryo. Methods for obtaining ESCs without destruction of embryos are known in the art and for example disclosed in Klimanskaya I. et al52.
In a particular embodiment of the invention, the organized 3D cell structures of mammalian cells are prepared using rodent homogeneous population of pluripotent or multipotent cells, in particular mouse ESC (mESC).
Otherwise stated, the disclosure provided herein by reference to ESCs also applies to PSCs, in particular iPSCs. Accordingly, in the disclosed embodiments ESC(s) and PSC(s) terms may be interchangeably used.
The “hypoSUMOylation treatment” according to the invention, designates a treatment applied to the cell culture that targets the molecular signaling pathway of the Epigenetic remodeling factor that is small ubiquitin-like modifier enzyme (SUMO enzyme), more particularly targets the molecular signaling pathway of the SUMO E1 activating enzyme. More precisely, the hypoSUMOylation treatment prevents small ubiquitin-like modifier (SUMO) conjugation to target proteins, predominantly to chromatin-associated proteins and leads to global hypermethylation of DNA (that can be in particular detected on enhancers heterochromatin, intergenic regions . . . ). According to the invention, hypoSUMOylation treatment is achieved using an agent known to inhibit small ubiquitin-like modifier (SUMO) (SUMO inhibito), in particular a small-molecule inhibitor of SUMO E1 enzyme. Increase in DNA methylation due to hypoSUMOylation treatment may be detected by genome-wide methylome, bisulfite-sequencing or other known techniques. Other phenomena associated with the hypoSUMOylation treatment according to the invention are highlighted in the Examples, especially in relation to
In a particular embodiment of the methods of the invention, the inhibitor of SUMOylation is a selective small-molecule inhibitor of SUMO E1 enzyme wherein the effect of hypoSUMOylation on DNA hypermethylation is partially mediated by Sall4 transcription factor known to regulate DNA methyltransferase Dnmt3a (Zhang. J. et al).
In a particular embodiment of the methods of the invention, the inhibitor of SUMOylation is a selective small-molecule inhibitor of SUMO E1 enzyme, in particular is ML-792. ML-792 (CAS No.: 1644342-14-2) is a molecule of the following formula (provided by Takeda) that is a selective inhibitor of SUMO-activating enzyme that interferes with the first step of the SUMOylation of proteins cascade catalyzed by the SUMO activating enzyme (SAE), SUMO E1. ML-792 belongs to adenosine sulfamate (AdoS) inhibitors of E1 enzymes and inhibits SUMO1 conjugation to target proteins that are known in the art as chromatin-associated proteins.
In a particular embodiment, ML-792 is used at a concentration of 1 to 2.5 μM for 48 h, more particularly a concentration of 2.5 μM.
According to another embodiment, the inhibitor of SUMOylation is a selective small-molecule inhibitor of SUMO E1 enzyme that is Tak-981 (2′,3′,4′-trihydroxy-flavone,2-2,3,4-Trihydroxyphenyl)-4H-1-Benzopyran-4-one; CAS number 144707-18-6). In a particular embodiment 0.1 μM of Tak-981 may be used for treatment for 48 h.
A culture medium used in the methods of the invention, in particular the designated first culture medium and second culture medium, is a medium suitable for culture of ESC. A culture medium suitable for use according to the invention accordingly sustains growth, proliferation and/or differentiation of cells. Such mediums are well known in the art and are commercially available (Gibco, Milteyni Biotec etc). Their composition may comprise Serum (Knockout™ DMEM, ES Cell qualified FBS, GlutaMAX™ Supplement, MEM Non-Essential Amino Acids, Penicillin-Streptomycin 2-Mercaptoethanol (Gibco)) and additional substances such as Lif (Miltenyi Biotec 130-099-895) (Serum+Lif is suitable for use as first culture medium) or may comprise N2B27 (Neurobasal™ medium, advanced DMEM/F-12, N-2 supplement, B-27™ supplement, Bovine Albumin Fraction V, GlutaMAX™ Supplement (Gibco)), and optionally additional substances such as antibiotics (penicillin-streptomycin) 2-mercaptoethanol and/or Lif (Miltenyi Biotec 130-099-895) (N2B27+Lif is suitable for use as second culture medium at least until gastruloid structure is reached). When the second culture medium is based on the use of N2B27, said second culture medium may be N2B27+Lif in a first stage of the culture until at least the EMLO gastruloid structures are obtained.
In an embodiment the second culture medium is N2B27+Lif until the end of the process.
In another embodiment, the second culture medium after EMLO gastruloid structures have been obtained, the medium may switch to a variant without Lif, especially N2B27 without Lif. According to this embodiment, Lif may be progressively eliminated from the culture, especially when the culture is performed using drops as disclosed herein.
Accordingly, the second culture medium may have a different composition over time of the culture being originally provided as N2B27+Lif until gastruloid structure is formed or recovered and then being provided as a variant thereof without Lif, e.g., as N2B27 without Lif, to pursue cell differentiation. Depending on the device used for the culture, Lif may be progressively eliminated from the culture by replacement with the second culture medium without Lif such as in the perfusion step when the culture is performed using drops.
According to an embodiment, N2B27+Lif composes the second culture medium until formation or recovery of gastruloid and the variant (without Lif) is used for the culture in hydrogel such as Matrigel. In Matrigel, when the second culture medium is free of Lif, ESC-L cells that have been useful to obtain the primitive streak are no longer maintained. This enables the differentiation of additional cell types (such as notochord and sclerotome) when compared to the culture in Matrigel in a second culture medium with N2B27+Lif.
The first culture medium for use according to the methods of the invention enables maintenance of the pluripotent state of the ESCs. The second culture medium for use according to the methods of the invention enables cell differentiation. In an embodiment, the second culture medium for use according to the invention after the ELS have been encapsulated within a hydrogel matrix using droplet fusion may be composed of a variant of the originally provided second medium such as the second culture medium however devoid of Lif, e.g., containing N2B27 without Lif.
The expression “second culture medium” hence defines either a single culture medium (single second culture medium) for cell differentiation or a combination over time of related culture mediums (combined second culture medium) wherein the firstly provided second culture medium comprises Lif and the then (later) provided second culture medium is devoid of Lif, such as in the combined second culture medium being N2B27+Lif and N2B27 without Lif.
In the method of in vitro preparing organized 3D cell structures of mammalian cells wherein the method comprises steps i. to v. as disclosed above, the second culture medium is advantageously a single second culture medium, in particular a single second culture medium comprising Lif, such as N2B27+Lif.
In the methods of the invention, the hypoSUMOylation treatment comprises transient steps (or rounds or waves) of hypoSUMOylation in the ESCs provided to carry out the methods of the invention. Steps of hypoSUMOylation may be sequential or may be repeated. Accordingly, the methods of the invention comprise at least two steps of hypoSUMOylation. In a particular embodiment, the methods of the invention comprise 3 steps of hypoSUMOylation. In a particular embodiment, the methods of the invention comprise exclusively (otherwise stated exactly (i.e. not less and not more)) two steps of hypoSUMOylation treatment. Repetition of the steps merely indicates that the number of steps of hypoSUMOylation treatment is more than 1, especially more than 2.
In a particular embodiment, the conditions (duration of the treatment and/or SUMO inhibitor) used to carry out the multiple steps of hypoSUMOylation treatment are independent for each step.
In a particular embodiment, a single SUMO inhibitor is used in at least the two initial steps of hypoSUMOylation treatment, in particular in all steps of hypoSUMOylation treatment. In a particular embodiment, the duration of the steps of hypoSUMOylation treatment is the same in at least the two initial steps of treatment, in particular is the same in all steps. In a particular embodiment, the SUMO inhibitor and the duration of the steps of hypoSUMOylation treatment are the same in the at least two initial steps, in particular are the same in all steps.
As disclosed herein, the steps of hypoSUMOylation must be separated in time in such a way that a subsequent step is separated from the immediately previous step by at least 3 days, in particular by less than 20 days or less than 15 days. The time between two consecutive steps of hypoSUMOylation treatment is calculated from the day after the final day of the treatment in the first of the considered consecutive steps to the day of the initiation of the treatment in the subsequent step. Calculation is schematically illustrated in the examples (
In a particular embodiment, two consecutive steps of hypoSUMOylation treatment are separated in time by at least 5 days, in particular by 5 to 15 days. In a particular embodiment, the duration of each step of hypoSUMOylation treatment is at least 24 hours, in particular is from 24 h to 72 h more particularly at least 48 h and especially is 48 h. This applies in particular when two steps of hypoSUMOylation treatment are carried out. In a particular embodiment, exactly (i.e. not less and not more) two steps of hypoSUMOylation treatment are performed in the methods of the invention wherein each step has a duration of 48 h and the steps are separated in time by 5 days. According to an embodiment the duration between two steps of hypoSUMOylation treatment with the selective inhibitor of SUMO E1 enzyme enables full recovery of the SUMOylation capability of the cells between the two consecutive steps of hypoSUMOylation treatment. Full recovery of the SUMOylation capability may be assessed by visualization of conjugated substrates by Western Blot (
The culture medium used in the methods of the invention are suitable for culture of ESCs. In addition, the first culture medium must enable maintenance of the pluripotency of the cells during the culture step, including during SUMOylation treatment and enables cell expansion and growth. The second culture medium must enable the obtained culture cells to differentiate. Otherwise stated the second medium is a medium permissive for cell differentiation. Such mediums are available in the art and illustrated by examples in the present disclosure. Such medium have been exemplified as single second culture medium and as combined second culture medium in the present disclosure.
In a particular embodiment, these mediums are Lif (Leukeamia inhibitory factor) containing medium or medium containing another STAT3 activator. In a particular embodiment, a medium with Lif is used in combination over time with a medium without Lif.
In a particular embodiment, the basal medium in the second medium is a serum-free medium such as N2B27 medium. In a particular embodiment after differentiation of the cells to reach 3D-organized cell structures, a variant of the second culture medium (i.e. a second culture medium without Lif, enabling cell differentiation) may be used as an alternative to the originally provided second culture medium. As an example, the basal medium is used as the variant of the said combined second culture medium after the differentiated cells (recovered as spheroid cells using the second culture medium) have been embedded in hydrogel such as Matrigel to prepare ELS. Accordingly, when gastruloid structures have been achieved in the microfluidic droplets, the culture medium may be free of Lif or other STAT3 activator.
In a particular embodiment of the methods of the invention, the first ESC culture medium is a Serum+Lif culture medium and the second ESC culture medium is a N2B27+Lif culture medium.
In a particular embodiment of the methods of the invention, the first ESC culture medium is a Serum+Lif culture medium and the second ESC culture medium is a N2B27+Lif culture medium until gastruloid structures have been formed or recovered and is then a variant thereof, i.e., N2B27 culture medium without Lif.
In another embodiment, the first ESC culture medium is serum+Lif medium with KSR (KnockOut™ Serum Replacement; Gibco #10828010) replacing ES Cell qualified FBS and the second culture medium is N2B27+Lif culture medium.
In another embodiment, the first ESC culture medium is serum+Lif medium with KSR (KnockOut™ Serum Replacement; Gibco #10828010) replacing ES Cell qualified FBS and the second culture medium is N2B27+Lif culture medium until spheroid cells are recovered and is then a variant thereof, i.e., N2B27 culture medium.
In another embodiment, the first ESC culture medium is N2B27+Lif+2i (PD0325901 and CHIR99021) medium (where 2i designates two inhibitory factors: dual inhibition of extracellular signal-regulated protein kinases ½ pathway and glycogen synthase kinase 3 beta) and the second medium is N2B27+Lif medium.
In another embodiment, the first ESC culture medium is N2B27+Lif+2i (PD0325901 and CHIR99021) medium (where 2i designates two inhibitory factors: dual inhibition of extracellular signal-regulated protein kinases ½ pathway and glycogen synthase kinase 3 beta) and the second medium is N2B27+Lif medium until gastruloid structures have been formed or recovered and is then a variant thereof, i.e., N2B27 culture medium without Lif.
In a particular embodiment of the methods of the invention, especially when using the above specified culture mediums, the inhibitor of SUMOylation is a selective small-molecule inhibitor of SUMO E1 enzyme, in particular is ML-792, in particular treatment with ML-792 is performed for 48 h in each hypoSUMOylation treatment step.
In a particular embodiment of the methods of the invention, especially when using the above specified culture mediums, and the inhibitor of SUMOylation ML-792, in particular when treatment with ML-792 is performed for 48 h in each hypoSUMOylation treatment step, two consecutive steps of hypoSUMOylation treatment are separated in time by at least 5 days, in particular by less than 15 days, more particularly the time between two consecutive steps of hypoSUMOylation treatment is 5 days.
In a particular embodiment of the methods of the invention, especially when using the above specified culture mediums, when the inhibitor of SUMOylation is the selective small-molecule inhibitor of SUMO E1 enzyme Tak-981, the treatment with 0.1 μM of Tak-981 is performed for 48 h in each hypoSUMOylation treatment step, and two consecutive steps of hypoSUMOylation treatment are performed, said steps being separated in time by 6 days.
According to a particular embodiment of the methods of the invention, the duration of one step of hypoSUMOylation treatment is independent of the duration of the other step(s) of hypoSUMOylation treatment.
According to an embodiment of the invention, when a further step of hypoSUMOylation treatment is performed, the culture medium in the additional step is one of the above disclosed mediums, especially is identical in composition to the first culture medium in particular is Serum+Lif culture medium.
In a particular embodiment of the methods of the invention, especially when performing the above embodiments for the hypoSUMOylation treatment with ML-792, the spheroids are recovered on day 15, preferably on day 18 and up to day 50 of culture calculated from the first day of the first step of hypoSUMOylation treatment.
In a particular embodiment when Tak-981 is used, the spheroids are recovered as soon as on day 14, preferably on day 16 and up to day 50 of culture calculated from the first day of the first step of hypoSUMOylation treatment.
According to a particular embodiment of the methods of the invention, the first step of hypoSUMOylation treatment is started as soon as the cells are provided in the culture medium in step i. in other words, the first day of the culture coincide with the first day of the first hypoSUMOylation treatment step. In another embodiment, the culture in the ESC suitable culture medium is started before the first day of the first hypoSUMOylation treatment step. According to the invention, increased DNA methylation may be obtained as soon as 8 days (D8) from the first day of first hypoSUMOylation treatment (when compared either to the cells at day 1 (D1) or to cells that remain untreated for hypoSUMOylation and otherwise cultured in the same conditions). Increased DNA methylation is accompanied by transcriptomic changes relating to expression of genetic markers. In these conditions ES-D8 cells are still able to self-renew and to differentiate into the 3 germ layers indicating maintenance of the pluripotency state, stable over cell passages. Organized 3D cell structures at a later stage, in particular after the second step of hypoSUMOylation treatment and as soon as spheroids are obtained lack cells with pluripotency state. The genetic markers of cells at these later stages are disclosed below and in the examples with respect to mammalian, especially mouse cells.
In a particular embodiment, cells may be retrieved at D8 after culture or initiation of the first step of hypoSUMOylation treatment (i.e. the method may be used to yield cells at this intermediate stage of preparation of organized 3D cell structures) as disclosed in step ii. and in the above conditions and used for DNA methylation study, in particular for screening of modulators of DNA methylation. In some embodiments, ES-D8 cells may be used to derive hypermethylated cell types such as hypermethylated neurons as cells for screening of modulators of DNA methylation.
ESCs yielded at D8 (D8_Hypermethylated_ESCs) may be those deposited at the CNCM (Collection Nationale de Cultures de Microorganismes, Institut Pasteur, 25-28, rue du Docteur Roux 75724 Paris Cedex 15—France) under number 1-5713 deposited on Jul. 19, 2021. These cells qualify as hypermethylated ES cells. They may be frozen after being provided in a suspension fluid of 10% DMSO in ES Cell qualified FBS (Gibco).
When the method of the invention is used for the preparation of organized 3D cell structures that are spheroids, in particular spheroids of mammalian cells, the recovered spheroids may in particular be adherent spheroids contained on adherent plates. Spheroids may be characterized by their cell diversity, using well known techniques in the art (such as FACS or RT-qPCR), in particular using Single-cell RNA-seq characterization as disclosed in the Examples (
Spheroids are expected to be obtained from day 15 from the onset of the first step of hypoSUMOylation treatment (that may coincide with the first day or the culture of the cells in the culture medium suitable for ESCs) if at least 2 steps of hypoSUMOylation treatment have been carried out that have enabled increase in DNA methylation of the cells. The spheroids are composed of at least three distinct self-assembled cell types encompassing from the center to the periphery of the spheroids embryonic stem-like cells (ES-like cells or ES-L), forming the core of the spheroid on a monolayer of epiblast-like cells (EPI-L cells) and surrounded by extraembryonic endoderm cells (XEN-like cells). The spheroids may alternatively be described as a core of ES-like cells, resting on epiblast-like cells and surrounded by XEN-like cells. The harvested spheroids are especially adherent spheroids.
In a particular embodiment, the cells in the spheroids lack pluripotency as may be evidenced by their inability to form colonies in a clonogenic assay (such as alkaline-phosphatase positive colonies) and their failure to activate retinoic acid-responsive genes. The identity of the different cell types in the spheroids may be assessed by Single-cell RNA-seq characterization and immunostaining. These spheroids may be obtained as adherent cell culture on plates.
In a particular embodiment, the spheroids are yielded as an adherent organized 3D cell structure that contain over 55% in particular 55% to 65.0% ES-like cells, over 29%, in particular 29.6 to 40% EPI-L cells and over 4.5% in particular 5% XEN-like cells.
In a particular embodiment, the spheroids may be characterized by cluster markers such as specific genes in the group of Nanog, Dppa3, Iftm3 for ESC-like cells, Sox17, Gata4, Gata6 for XEN-like cells and Pou3f1, Fgf5, Wnt3 for EPI-like cells, in particular Dppa3, Sox17 and Pou3fl respectively. These markers may be detected by RT-qPCR. It is noted that ESC-like cells, by contrast to ESC express specific primordial germ cell markers including Dppa3, Ifitm1 and Iftm3.
In a particular embodiment, the spheroids may be additionally characterized by cluster markers expressed on cell membranes such as Cd24a for EPI-like cells, Pgfra (Cd140) for XEN-like cells and Cd31 (Pecam1) for ES-like cells. These markers may be detected by FACS.
In a particular embodiment the spheroids of the invention are an adherent organized 3D cell structure yielded at day 18 (D18) that contains three types of cells i.e., EPI-like cells related to the epiblast of the mouse embryo development (E4.5-E5.5), XEN-like cells related to the extraembryonic endoderm (E4.5-E6.5) and ESC-like expressing markers of ESC and markers of pluripotent state of PGC cells (Primordial Germ Cells). Such adherent organized 3D cell structure yielded at day 18 (designated D18_Spheroid_cells) has been deposited at the CNCM (Paris-France) under number 1-5754 on Sep. 28, 2021. These deposited D18_Spheroidcells express the membrane markers Cd24a (for EPI-like cells), Pdgfra (Cd140) (for XEN-like cells) and Cd31 (Pecam1) (ESC-like) and the markers of specific sub-types Pou3f1, Fgf5, Wnt3, Sox17, Gata4, Gata6, and Nanog, Dppa3, Iftm3. They may be stored in suspension fluid such as 10% DMSO in ES cell Qualified FBS (Gibco 16141-079). In a particular embodiment of the invention, the spheroids may be used to model cancer progression and metastasis as cell adhesion molecules that may be expressed by the spheroids also significantly influence cancer progression and metastasis. In a particular use, the spheroids may accordingly be suitable for screening (in particular high throughput screening) of molecules capable of modulating, in particular inhibiting 3D shape establishment of cells.
The methods disclosed above are in particular carried out without steps of providing morphogen substance to the cells.
In a further aspect, the invention relates to a method as disclosed above that may give rise to spheroids, wherein the method comprises additional steps after recovering the spheroids wherein the steps comprise:
The non-adherent microwell plate may be an AggreWell™ plate (StemCells Technologies) or another system that enables aggregation of cells in controlled conditions allowing medium exchange during cell culture such as InSphero GravityPLUS Technology or a microfluidic device (microfluidic chip). In a particular embodiment, each microwell contains 70 to 130 cells, in particular 100 cells and the culture is carried out for 3 to 4 days, in particular 3 days, The transfer of cells may be carried out as a seeding step of dissociated cells. The dissociated cells may be provided as a homogenous suspension of these cells. In a particular embodiment, the transfer of cells includes a step of passage of the spheroid culture and a step of obtaining a cell suspension used to seed dissociated cells in the wells of a plate.
In a particular embodiment, the transfer of spheroid cells is performed on day 18 and the recovery of self-organized grown elongated structures is performed on day 21 after the first step of hypoSUMOylation treatment has been initiated on the homogeneous population of pluripotent or multipotent mammalian cells.
As the recovered 3D-self-organized grown structures exhibit the 3 primary germ layers (ectoderm, endoderm, mesoderm) of the organism development they may be designated as gastruloids, i.e. a multicellular in vitro model of a gastrulating embryo obtained without using embryo.
According to a particular embodiment, gastruloids obtained according to the invention may be characterized by specific markers such as T for mesodermal transcription factor brachyury, Cer1, Hoxb9, En1, and additional markers such as Nanog and Pou3f1. These markers may be detected by RT-qPCR or immunostaining.
In a particular embodiment, the obtained gastruloids lack some types of cells such as primordial germ cell precursors, the notochord and they lack the extra-embryonic tissues that are found in the gastrulating embryo.
It is pointed out that the obtained gastruloids may exhibit different phenotypic outcome depending on the culture plate, in particular microwell plate or microfluidic chip used.
In a particular embodiment of the invention, the gastruloids may be used to differentiate into multiple cell types with therapeutic potential. In another embodiment, the gastruloids may be used as an in vitro model to study or screen molecules or agents influencing development, in particular to study developmental toxicity of molecules. In another embodiment, the gastruloids may be used in vitro to produce molecules of therapeutic interests including growth factors, cytokines, morphogens, chemokines. Such molecules may in particular act as immunomodulating agents, rejuvenating agents, anti-aging agents . . . .
In a further aspect, the invention relates to a method as disclosed above that may give rise to spheroids, wherein the method comprises additional steps after recovering the spheroids wherein the steps comprise:
The step of seeding dissociated cells may be performed after a step of passage of the spheroid culture and a step of obtaining a cell suspension used to seed dissociated cells in the microfluidic device. In particular, the transfer of the cells in the microfluidic device is carried out using droplets containing the cells (e.g. one droplet may comprise 60 to 300 cells, in particular 120 or 200 cells).
After the self-organized grown structures showing elongation with an anterior-posterior body axis such as gastruloid structures have been obtained in the microfluidic device, these structures may be recovered for seeding into a plate suitable for embedding the structures in a solution of Matrigel (e.g. 20% Matrigel) or an equivalent matrix as disclosed herein contained into cell culture medium (such as N2B27+Lif medium or N2B27+Lif followed by switch to a variant thereof devoid of Lif) for incubation to promote further elongation of the structures, especially to achieve embryo-like structures.
Alternatively, after the self-organized grown structures showing elongation with an anterior-posterior body axis such as gastruloid structures have been obtained in the microfluidic device, these structures contained in first droplets may be brought into contact with second droplets for fusion of the first and second droplets, wherein the second droplets contain Matrigel (e.g. 40% Matrigel) or an equivalent matrix as disclosed herein to yield fused drops, such as drops containing 20% Matrigel, that are allowed to gelify. These drops are suitable for further culture of the self-organized grown elongated structures. In some embodiments, the Matrigel or equivalent matrix is in a proportion of 10% to 40% of the contents of the drop resulting from the fusion. In an embodiment, the second culture medium after the Matrigel of equivalent matrix has been brought is devoid of Lif, in particular is N2B27 without Lif. According to such embodiment, the second culture medium in the first droplets is a second culture medium with Lif, such as N2B27+Lif and the second culture medium used after fusion with the second droplets is a second culture medium without Lif, such as N2B27. The second culture medium according to this embodiment is a so-called combined second culture medium.
Accordingly, the invention relates to a method as disclosed above that may give rise to spheroids, wherein the method comprises additional steps after recovering the spheroids wherein the steps comprise:
This method according to the invention enables the preparation using a microfluidic device, advantageously a droplet microfluidics platform as disclosed herein, and using a Matrigel matrix or an equivalent matrix of poly(ethylene glycol) (PEG) hydrogel, Geltrex (Thermo Fisher) GrowDex (UPM biomedicals) HyStem® hydrogels to obtain embryoid structures derived from ES or PS cells i.e., obtained without using embryo.
The terms “drop(s)” or “droplet(s)” are used interchangeably in the present description. These terms may designate structures that may have a different size such as to disclose that fusion of droplets result in a larger structure of droplet that may be designated as a drop.
The steps of culture in the Matrigel or equivalent matrix as disclosed herein may be carried out for at least 2 days, in particular for 7 to 14 days.
Using the microfluidic platform, the inventors have found that after mechanical immobilization into anchors using hydrogel and performing oil-to-medium phase change, the device allows the application of controlled feeding/perfusion strategies (e.g. to allow periodic stimulation etc.) for further embryoid maturation (i.e. controlling fluid dynamics), in particular at a low Reynolds number, combined with in situ imaging which would not be currently achievable in regular 96-well plates or rotating bioreactor.
In a particular embodiment, the embryoids are remarkable in that they comprise Schwann cell precursors, dermomyotome, spinal cord cell types.
In a particular embodiment, the obtained embryoids lack some types of cells such as cells or primordial germ cell precursors, forebrain tissue and/or the notochord and they lack the extra-embryonic tissues that is found in the embryo.
In a particular embodiment of the method of obtaining such embryoids, the transfer of spheroid cells is performed on day 18 (D18) and the recovery of self-organized grown elongated structures is performed on day 25 (D25) after the first step of hypoSUMOylation treatment has been initiated on the homogeneous population of pluripotent or multipotent mammalian cells. According to a particular embodiment, embryoids also designated herein embryo-like structures (ELS) obtained according to the invention may be characterized by specific markers such as at least one and up to all of Uncx, En1, Tuj1, Pax2, Map2 Dmrt2, Cd93, Tnnt2, Rfx6, Sox10, Pax1, Pax9, Noto, Shh, Foxg1, Emx1 and Vsx2 or at least one and up to all of Uncx, En1, Tuj1, Pax2, Map2 Dmrt2, Cd93, Tnnt2, Rfx6, Sox10, Pax1, Pax9, Noto, Shh, Foxg1, Emx1, Vsx2, Nkx6-1 and My4. According to a particular embodiment, at least cardiomyocytes marker Tnnt2 is expressed. According to a particular embodiment, cardiomyocytes markers Tnnt2 and My14 are expressed. According to a particular embodiment, embryoids obtained according to the invention may be characterized by specific markers such as at least one and up to all of Uncx, En1, Tuj1, Pax2, Map2 Dmrt2, Cd93, Tnnt2, Rfx6 and Sox10 or as at least one and up to all of Uncx, En1, Tuj1, Pax2, Map2 Dmrt2, Cd93, Tnnt2, Rfx6, Sox10 and My14. According to a particular embodiment, embryoids obtained according to the invention may be characterized by specific markers such as Tnnt2, Noto, Shh, Foxg1 and Emx1. According to a particular embodiment, embryoids obtained according to the invention may be characterized by specific markers such as Tnnt2, My14 Pax1, Pax9 Nkx6-1 and Vsx2 or Tnnt2, Pax1, Pax9 and Vsx2.
In a particular embodiment of the invention, the embryoids may be used to differentiate into multiple cell types with therapeutic potential. In another embodiment, the embryoids may be used as an in vitro model to study or screen molecules or agents influencing development, in particular to study developmental toxicity of molecules. In another embodiment, the embryoids may be used in vitro to produce molecules of therapeutic interests including growth factors, cytokines, morphogens, chemokines. Such molecules may in particular act as immunomodulating agents, epigenetic drugs, rejuvenating agents, anti-aging agents . . . .
The invention also relates to an organized 3D structure which is self-assembled into spheroid wherein the spheroid comprises mammalian cell clusters encompassing 3D-organized ES-like cells as a core resting on EPI-like cells and surrounded by XEN-like cells, in particular wherein the cell types lack pluripotency. In a particular embodiment, the mammalian cells in the organized 3D structure are not human cells or are not exclusively human cells. In a particular embodiment, the mammalian cells in the organized 3D structure comprise or consist of human cells or are not exclusively human cells.
In another embodiment, the invention relates to an organized 3D structure which is self-assembled into a structure of mammalian cells with Head-to-tail body axis which is:
In a particular embodiment these elongating-multilineages-organized (EMLO) embryoids have been obtained in a culture device that is suitable for drop adjustment and culture or in a microfluidic platform, as described herein.
In a particular aspect, the invention concerns also the use of a spheroid structure obtained according to the method of the invention, for screening of molecules, in particular for high throughput screening of molecules for assessing their activity on 2D to 3D transition of cell culture, in particular for assessing their capability to interfere with 2D to 3D transition. The screened molecules may be anti-cancer drug candidates.
The invention also relates to the use of elongating-multilineages-organized (EMLO) gastruloids obtained according to the method of the invention, or elongating-multilineages-organized (EMLO) embryoids obtained according to the method of the invention, in particular of non-human mammalian EMLO gastruloids or embryoids, (i) for screening of molecules, in particular for high throughput screening of molecules for assessing their activity on development in particular on developmental toxicity or (ii) for the production of growth factors, cytokines, morphogens, chemokines of interest, in particular for interest for therapeutic use or (iii) for the production of cells for therapeutic potential.
When the elongating-multilineages-organized (EMLO) gastruloids or the elongating-multilineages-organized (EMLO) embryoids are obtained according to the method of the invention using the microfluidic platform, the platform allows controlled droplet fusion for combinatorial screening or for temporally controlling hydrogel encapsulation.
Besides, elongating-multilineages-organized (EMLO) gastruloids or embryoids obtained according to the method of the invention provide structures with cellular complexity that is generally not achieved with specialized organoids. The structures obtained according to the invention, thus provide improvements in making available 3D-cell structures for therapeutic applications, in particular for those requiring long-term viability and extended maturation potential including elements of the angiogenesis and immune cell maturation. Accordingly, elongating-multilineages-organized (EMLO) gastruloids or embryoids obtained according to the method of the invention provides structures for cell-based therapy. In particular these structures may be of interest in providing transplantation material for neural tissue repair or therapy of autoimmune, cardiovascular, skeletal or liver diseases.
Elongating-multilineages-organized (EMLO) gastruloids may exhibit particularly interesting potential in regeneration therapy of neural cells damage or injury, in particular leading to neurodegenerative situation in animals or humans, such as Spinal Cord Injury (SCI), due to their capability to generate neural and endothelial lineages from ectodermal and mesodermal lineages respectively, without interference of more specialized cells.
Accordingly, elongating-multilineages-organized (EMLO) gastruloids or embryoids obtained according to the method of the invention provide structures for grafting or transplanting in an organism in need thereof, suitable to provide a combinatorial therapeutic strategy bringing both cell replacement and sourcing growth promoting molecules and more generally trophic support.
In a particular embodiment of the invention, use of the spheroid structure or use of the elongating-multilineages-organized (EMLO) structures obtained according to the methods of the invention may involve manipulation of the structures within immobilized droplets as disclosed herein. According to this aspect of the manipulation protocol, a drop containing the cell aggregates of the invention may be provided in the culture chamber and fused with a drop containing molecules to be assayed or more generally biomaterial (including agarose for immobilization, dyes). After the structures of the invention have been enabled to react with the molecules or biomaterial provided, they can be recovered for analysis, in particular by cytometry, RT-qPCR, single cell RNA-sequencing, immunostaining . . . .
Culture of spheroid structure or of elongating-multilineages-organized (EMLO) structures in immobilized drops according to the invention provides the advantageous property that culture volumes may be reduced up to about 15 times without impacting aggregation kinetics, expansion degree and level of marker expression showing unaltered cell function with respect to culture on low adhesion 96-well plates. Volume reduction provides in particular the advantage of improving study of the role of para/autocrine signaling.
The invention also relates to a plurality of organized 3D cell structures as defined herein, wherein each of the plurality of organized 3D structures comprises cells having the same nuclear genome.
The invention also relates to a plurality of organized 3D cell structures as defined in the invention, wherein each of the plurality of organized 3D structures is provided in a culture medium.
The invention also relates to a culture or a storage means chosen from a plate of microwells, a collection of droplets, or a microfluidic device comprising cell traps wherein said each of said microwells, droplets or respectively cell traps is loaded with an organized 3D cell structure and the plate of microwells, collection of droplets, and respectively microfluidic device comprise a plurality of organized 3D cell structures according to the invention.
The invention also relates to a combination product comprising A) an organized 3D cell structure which is self-assembled into a spheroid according to the herein disclosed embodiments, and B) a homogeneous population of pluripotent or multipotent vertebrate cells, wherein the organized 3D cell structure of A) and the homogeneous population of B) both comprise cells having the same nuclear genome The invention also concerns a method of providing a cellular therapy to a patient in need thereof, comprising (i) providing an organized 3D cell structure as defined herein, (ii) obtaining cells of one or more cell types from the organized 3D cell structure, and (iii) administering the cells of one or more cell types to the patient.
In a particular embodiment of this method the cells of one or more cell types of (ii) are cultured, passaged and/or differentiated before the administration to the patient.
The invention also relates to a method of providing a cellular therapy to a patient in need thereof, comprising (i) providing an organized 3D cell structure which is self-assembled into a structure of mammalian cells with Head-to-tail body axis according to the invention, (ii) obtaining cells of one or more cell types from the organized 3D structure, and (iii) administering the cells of one or more cell types to the patient.
In an embodiment of this method, the cells of one or more cell types of (ii) are cultured, passaged and/or differentiated before the administration to the patient.
In a further aspect, the invention relates to microfluidic device comprising a body having a thickness and comprising a bottom side and a top side facing each other, said bottom side being arranged at distance with a plate so as to define a channel for the flow of a fluid between at least one inlet and at least one outlet, said body comprising at least one trap extending along an axis of revolution with said trap comprising a first part and a second part extending along said axis of revolution, the first part being arranged, along said axis of revolution, between the second part and an opening of the trap that opens out at the bottom side in the channel, wherein the surface of a cross-section of the first part at the opening is greater than the surface of a cross-section of the second part and wherein the diameter of the opening is greater than or equal to twice the distance between the plate and said opening.
In the present invention, the axis of revolution is an axis around which the internal surface of the cavity is formed and forms in cross-section a closed contour.
The microfluidic device allows the trapping of a first droplet by capillarity in the first part of the cavity of a trap. The first droplet migrates to the second part of the cavity of said trap by buoyancy after a given time, thus liberating the first part of the cavity of the trap and allowing possibly but not necessarily the trapping of a second droplet in the same trap.
This proposed device is unique for immobilizing and manipulating liquid droplets with a volume comprised between 4 and 10 μL, while promoting the long-term culture and differentiation of pluripotent stem cells (PSCs). Another important aspect is this volume range has been characterized as the minimal volume enabling the aggregation and culture of PSCs in 3D.
According to the invention, the fact that the surface of a cross-section of the first part at the opening is greater than the surface of a cross-section of the second part, facilitates trapping of a droplet by gravity and allows the droplet to adopt a convex shape at its bottom tip when trapped in the second part. Compared to bottom of the convex shape at the bottom tip of the first droplet eases the sedimentation of the cells at the droplet bottom and a faster aggregation of the cells.
The diameter of the opening being greater than or equal to twice the distance between the plate and said opening, allow a trapping by capillarity by facilitating the release of the surface energy of a droplet.
The first part may comprise a convex annular wall having a peripheral free edge defining said opening of each cavity.
The channel may comprise a diffusion area for diffusion of the droplets connected to said at least one inlet and a collect area connected to said at least one outlet. Those area may have a triangular shape. Said at least one inlet opens out into said diffusion area and said at least one outlet opens out into said collecting area.
Said body and said plate may be single piece made or made of two distinct pieces. Said plate may be made of a transparent material allowing an observation of the at least one cavity through said plate. It should be noted that the microfluidic device may comprise a plurality of traps. Also, said traps may be arranged in rows, which are staggered along a direction extending between said at least one inlet and said at least one outlet.
According to the invention, when brought into the cavity of the traps, the first or the second droplets comprise cells, in particular cells recovered from culture and treatment according to the methods of the invention, especially mammalian cells as disclosed herein that have achieved a degree of 3D-structure organization such as gastruloids and embryoids disclosed herein. Besides, cells that have been brought into the cavity of the traps are allowed to grow in the drop as further organized 3D-structures such as gastruloids or embryoids according to the invention when the other droplets brought to the cavity provides in particular cell culture medium and optionally Matrigel or equivalent matrix as disclosed herein.
In a particular embodiment, the traps may all be identical in the microfluidic device.
The cavity of each trap is a blind hole and as such also serves as a chamber for the culture and growth of the provided cells in the drop. In other words, each cavity comprises a bottom that may be concave.
In a particular embodiment, the body may be parallelepipedic. Alternatively, the body may present a circular cross-section.
In a particular embodiment, the axis of revolution may be perpendicular to the top and/or bottom side of the body and/or the plate. The configuration within which the axis of revolution is substantially perpendicular to the bottom side and the plate may be considered as a preferred embodiment since it allows the maximum gravity forces to apply so as to promote the full droplets capture into the traps, when the microfluidic device rests horizontally on the plate when in operation.
The top and bottom sides may be parallel. In another embodiment, the axis of revolution may be tilted with regards to the top and/or bottom side of the body.
The annular wall of the first part of the cavity, of at least one or each trap, may be convex with regards to the axis of revolution.
For at least one, or for each trap, the cavity may be delimited in its second part by a cylindrical wall having a hexagonal cross-section. Accordingly, the cross section of the second part of the cavity of said trap may be constant along the axis of revolution. Such cross section allows the formation or the growth of organized 3D-structures of cells, such as spheroids as disclosed herein, and their growth as elongated structures to form gastruloids or embryoids according to the invention, when one or more droplets are trapped in the trap and provided with suitable culture medium.
For at least one, or for each trap, the cross section of the first part of the cavity of said trap, respectively the cross section of the second part of the cavity of said trap, may be comprised in a plane perpendicular to the axis of revolution.
In a particular embodiment, the dimension of the second part of the cavity of at least one or each trap along the axis of revolution (i.e. the height of the second part), may be at least five times the dimension of the first part of the cavity of at least one or each trap along the axis of revolution (i.e. the height of the first part).
In a particular embodiment, the dimension of the first part of the cavity of at least one or each trap, along the axis of revolution may constitute from 2% to 20% of the total dimension of the trap along the axis of revolution (i.e. the total height of the trap).
In a particular embodiment, the dimension of the second part of the cavity of at least one or each trap, along the axis of revolution may constitute from 80% to 95% of the total dimension of the trap along the axis of revolution.
In a particular embodiment, the opening, of at least one or each trap, may be circular. The diameter of the opening may be comprised from 2 to 3 mm, in particular from 2.2 to 2.6 mm, in particular equal to 2.4 mm. This arrangement promotes the trapping by capillarity of an initial droplet in the trap. These particular dimensions are well adapted for the manipulation of the first droplets of 7 μl.
In a particular embodiment, the diameter of the cross-section of the second part of the cavity, of at least one or each trap, may be comprised from 1 to 2 mm, in particular from 1.1 to 1.3 mm, in particular equal to 1.2 mm. The diameter of the cross-section of the second part of the cavity, of at least one or each trap, may be the diameter of an inscribed circle of the cross section of said second part of the cavity. This arrangement allows full trapping of a droplet inside the trap, by buoyancy and allows promoting a moderate level of said droplet confinement in the trap which prevents damaging the droplets inside the trap.
In an embodiment, each trap opens out in a channel formed by a recess arranged in the body on the side containing the opening of the traps, i.e. the bottom side of the body. In an embodiment, the bottom side may comprise an annular rim surrounding an internal bottom face and the traps that open out onto said internal bottom face. The microfluidic device may comprise a unique channel. The channel may extend in a plane parallel to the bottom side of the body and may have a hexagonal shape and may cover all the openings of the traps.
In an embodiment, the diameter of the opening, of at least one or each trap, may be greater than two times the dimension of the channel along the axis of revolution of the cavity. This arrangement promotes the trapping by capillarity of at least a droplet in the trap.
In a particular embodiment, the dimension of the channel along the axis of revolution (i.e. the height of the channel) may be comprised from 0.5 to 2 mm, in particular equal to 1 mm. The channel allows a moderate level of confinement of droplets circulating in the channel.
In an embodiment, the curvature of the convex annular wall of the first part of the cavity, of at least one or each trap, may increase towards the opening along the axis of revolution. In another embodiment, the radius of curvature may be constant on the annular wall and may be around 0.5 mm.
In a particular embodiment, the dimension of each trap along the axis of revolution may be comprised from 2 to 6 mm, in particular from 3 to 5 mm, in particular may be equal to 4 mm.
Such arrangement promotes full trapping of a droplet inside the second part of the cavity of the trap comprising said droplet and thus leaving an empty space at the first part of the cavity of the trap to anchor another droplet in the same trap. Besides, this arrangement promotes the contact between the two droplets in said trap.
In a particular embodiment, the dimension of each trap along the axis of revolution (i.e. the total height of the trap) may be proportional to the volume of the droplets intended to be introduced in the microfluidic device.
In a particular embodiment, the distance between two adjacent traps may be comprised from 5 to 10 mm, in particular 7 to 9 mm, to in particular equal to 8 mm. This design limits the contact between the droplets. This distance between two adjacent traps may be measured between the axis of revolution of the respective traps.
In a particular embodiment, the microfluidic device may comprise a number of traps from 2 to 100, in particular may comprise 81 traps arranged along 9 columns. This arrangement provides a convenient number of biological replicates.
In an embodiment, the cavity of each trap may comprise a third part arranged at an end of the cavity opposite to the opening. The third part may be delimited by a concave wall forming a dome.
The microfluidic device may further comprise at least one duct forming an inlet of the microfluidic device into the channel. Said at least one duct is formed in the body and opens out at a first one end at the top side of the body and at an opposite second end into the channel.
More particularly, the duct opens out in the diffusion area.
In a particular embodiment, the duct is tilted, with respect to the bottom side of the body, by an angle comprised from 30° to 60°, in particular equal to 45°. The orientation of the duct avoids droplet breaking at the entrance in the channel and also avoids loose liquid when injecting liquid into the microfluidic device.
The second end of said at least one duct may comprise an annular convex wall that prevents the droplets from breaking when droplets are introduced into the channel.
In a particular embodiment, the microfluidic device may comprise at least two rails arranged in the channel, suitable for guiding the droplets, outputted from the duct, to the traps. The rails guide the droplets evenly inside the channel. Each rail may be formed by a groove formed in the bottom side of the body or in the plate and having a depth smaller than two times the dimension of the channel along the axis of revolution. Each rail may have a depth of 0.5 mm.
In a particular embodiment, the body may comprise at least two microfluidic outlets that are formed by outlet conduits arranged at an end of said body that is opposite to said at least one inlet. Each outlet conduit is connected to the channel and may extend substantially vertically.
The body may comprise three or four microfluidic outlet conduits. The outlet conduits open out in the top side of the microfluidic device. Those outlets limit the hydrostatic pressure inside the microfluidic device.
In another embodiment, the microfluidic device may comprise a plurality of inlets and a plurality of outlets. These inlets and outlets are formed in the body of the microfluidic device.
In a particular embodiment, the microfluidic device may comprise at least two inlets and at least two outlets. The microfluidic device may comprise the same number of inlets and outlets.
Each inlet may be associated to one single outlet. Moreover, the microfluidic device is configured such that fluid entering by one specific inlet, flows through the channel and to one specific outlet. In another embodiment, the microfluidic device comprises three inlets and/or three outlets.
The body of the microfluidic device may have a substantially parallelepiped shape that comprises a first longitudinal axis corresponding to the direction of fluid flow, a second transverse axis and third axis corresponding to the thickness of the body. The inlets may be spaced, in the second direction, by a distance substantially equal to the distance spacing the outlets in the second direction. In this manner, the liquid entering one inlet tends to flow towards the outlet that is aligned with the inlet according to the first longitudinal direction. In this manner, should the microfluidic device comprise N inlets and N outlets, the fluid entering through one inlet k (k being comprised in the range 1 to N) flows through the channel and to the outlet k without mixing with the first adjacent fluid flowing from the inlet k−1 through the channel to the outlet k−1 and without mixing with the second adjacent fluid flowing from the inlet k+1 through the channel to the outlet k+1.
In a particular embodiment, the diameter of the opening, of each trap, may be comprised from 2.2 to 2.6 mm, and the diameter of the cross-section of the second part of the cavity, of each trap, may be comprised from 1.1 to 1.3 mm.
In a particular embodiment, the diameter of the opening, of each trap, may be comprised from 2.2 to 2.6 mm, and the diameter of the cross-section of the second part of the cavity, of each trap, may be comprised from 1.1 to 1.3 mm, and the dimension of each trap along the axis of revolution may be comprised from 3 to 5 mm.
In a particular embodiment, the diameter of the opening, of each trap, may be comprised from 2.2 to 2.6 mm, and the diameter of the cross-section of the second part of the cavity, of each trap, may be comprised from 1.1 to 1.3 mm, and the dimension of the channel along the axis of revolution may be comprised from 0.5 to 2 mm.
In a particular embodiment, the dimension of each trap along the axis of revolution may be comprised from 3 to 5 mm, and the dimension of the channel along the axis of revolution may be comprised from 0.5 to 2 mm.
In a particular embodiment, the microfluidic device may comprise four rails, arranged in the channel, and the duct connecting the outside of the microfluidic device to the channel may be tilted, with respect to the bottom side of the body, by an angle comprised from 30° to 60.
In a particular embodiment, the body and the plate may be made of polymer such as polydimethylsiloxane (PDMS). Also, they may comprise each a material or any combinations of materials selected from, but not limited to, silicone rubber (i.e. polysiloxane), crystalline silicon, poly(dimethylsiloxane) (PDMS), silica (e.g., quartz and glass), thermoplastics (e.g., poly(methyl methacrylate) (PMMA), polycarbonate (PC), polystyrene (PS), poly(ethylene glycol) diacrylate (PEGDA), polyurethane (PU), perfluorinated compounds (e.g., perfluoroalkoxy (Teflon PFA) and fluorinated ethylenepropylene (Teflon FEP)), and polyolefins (e.g., cyclic olefin copolymer (COC), cyclic olefin polymer (COP), cyclic block copolymer (CBC), and polyvinyl chloride (PVC)), polyimide (PI), poly(lactic-co-glycolic acid) (PLGA), thermoset polyester (TPE), off-stoichiometry thiol-ene (OSTE), transparent ceramics such as aluminum oxide (Al2O3), spinel (MgAl2O4), yttria alumina garnet (YAG), and neodymium-doped yttria alumina garnet (Nd:YAG), and paper (e.g. transparent or translucent paper). In a particular embodiment, the first element and the second element comprise silica (e.g., quartz and glass). In another embodiment, the first element and the second element comprise poly(dimethylsiloxane) (PDMS), thermoplastics (e.g., poly(methyl methacrylate) (PMMA), polycarbonate (PC), polystyrene (PS), polyurethane (PU), perfluorinated compounds (e.g., perfluoroalkoxy (Teflon PFA) and fluorinated ethylenepropylene (Teflon FEP)), and polyolefins (e.g., cyclic olefin copolymer (COC), cyclic olefin polymer (COP), cyclic block copolymer (CBC), and polyvinyl chloride (PVC)), poly(lactic-co-glycolic acid) (PLGA), thermoset polyester (TPE).The body of microfluidic device may be fabricated by molding. The body and/or the plate may be made using additive manufacturing techniques.
In a particular embodiment, the plate may be made of glass.
According to an embodiment, the invention relates to a manufacturing process of the microfluidic device disclosed herein, said manufacturing process may comprise the following steps:
The polymer may be PDMS and the curing agent may be present at a ratio of 1:10, for example the volume of the curing agent may be for about 50-60 mL. The curing agent may be a chemical mixture sold with the PDMS base elastomer, for which the formulation is proprietary. The base contains a linear chain of siloxane with dimethyl groups and with Si-vinyl end groups, and a Pt catalyst complex. The curing agent is rich in Si—H bonds and may also contains other oligomers such as tetramethyl tetravinyl cyclotetrasiloxane (Venkatachalam et al., Ceramic International, 2019).
The plate slide may be a 75×50 mm rectangular. The plate slide may be made of glass or polymer. The plate slide may be bounded by plasma for two rounds of 40 seconds and by heating the resulting microfluidic device at least at 80° C., for at least 2 hours. The glass slide can be replaced by Polycarbonate, Polystyrene etc.
The fluorophilic coating may be fixed to the microfluidic device by heating the microfluidic device at least at 110° C., for three rounds.
In a further aspect, the invention relates to a method of manipulating droplets using the aforementioned microfluidic device, the method comprising:
According to another feature of the method, it may comprise:
The step (M2) promotes gravity forces in order to allow the droplets' motion inside the microfluidic device. The step (M5) allows to adjust the gravity forces in order to favor a second drop trapping in the anchors by capillary forces.
The first angle promotes gravity forces in order to allow the droplets motion inside the channel.
The second angle helps controlling the gravity forces in order to favor a second droplet trapping in the traps of the first part of the cavity by capillary forces.
In an embodiment, in the step (M2) and/or the step (MS), the microfluidic device may be tilted such as the outlets of the microfluidic device are above the horizontal axis while the inlet of the microfluidic device is bellow of the horizontal axis.
In a particular embodiment of the invention, the first droplets may be created by plugs of aqueous phase having a volume comprised from 5 μL to 10 μL, in particular equal to 7 μL. The first liquid composition may further comprise plugs of a fluorogenic oil having a volume comprised from 5 μL to 10 μL, in particular equal to 6 μL, said plugs of fluorogenic oil separating the first droplets during fabrication of the droplet before injection of the first liquid composition in the microfluidic device. The fluorogenic oil may contain a fluorogenic surfactant at 0.5% of the total weight.
In an embodiment, the method may comprise before step (M4) a step of flushing an immiscible fluorocarbon oil without surfactant in the traps.
In a particular embodiment of the invention, the second droplets may contain soluble molecules such as culture medium, dyes, or a biomaterial.
In some embodiments the second droplets may contain Matrigel or equivalent matrix as disclosed herein to provide gelified drops after fusion of the first and second droplets in step (M6). In such embodiments the Matrigel or equivalent matrix is in a proportion of 10% to 40% of the contents of the drop resulting from the fusion, in particular of about 20% of the contents of the drop resulting from the fusion when the hydrogel is Matrigel.
Besides, the first liquid composition and/or the second liquid composition may be introduced in the microfluidic device at a flow of 1000 μL/min.
In a particular embodiment of the invention, the method may comprise before step (M4) a step of placing the microfluidic device in an incubator set up at 37° C. and 5% of CO2 to allow cells culture. The cross section of the second part of the cavity promotes shaping the first droplet in a spheroid shape.
In some embodiments, after step (M6) when oil phase is present surrounding the gelified drops said oil phase is replaced by culture medium. In some embodiments culture medium is then renewed at chosen time intervals such as every 2 days.
In an embodiment, the first or the second droplets, in particular the first droplets, may comprise cells, in particular may comprise a homogenous population of pluripotent or multipotent vertebrate cells, in particular non-human mammalian cells, more particularly rodent cells or alternatively may comprise a homogenous population of pluripotent or multipotent human cells.
The method of using the microfluidic device according to the invention, in particular the method of manipulating droplets as disclosed herein may be implemented in the culture illustrated in the Examples such as in the culture disclosed in relation to
The invention will be further disclosed in the Examples and the figures that follow which highlight specific non limiting features and embodiments.
Cell Culture
Mouse ES-R1 cells14 were used for most experiments and were maintained in serum+Lif medium (KnockOut DMEM supplemented with 15% ES cell qualified FBS, 1% GlutaMAX, 1% MEM non-essential amino acids, 1% penicillin-streptomycin, 0.1 mM 2-mercaptoethanol, 10 ng/mL Lif (Miltenyi Biotec #130-099-895)) on gelatin-coated plates in a humidified incubator (37° C., 5% CO2). The Sox1::eGFP-T::mCherry double reporter CGR8 mouse ES cells (gift from David M. Suter, Swiss Federal Institute of Technology, Lausanne, Switzerland, ref.56) were maintained on Mitomycin C-treated mouse embryonic fibroblast feeder cells in serum+Lif medium, and the MERVL::tdTomato-Dppa2/4 DKO mouse ES-E14 cells (gift from Wolf Reik, Babraham Institute, Cambridge, UK57) were cultured in serum+Lif medium on gelatin-coated plates. Mouse ES-D3 cells (from ATCC) were used for droplet-microfluidic platform validation experiments and were cultured in ESLIF medium as previously described10.
For 2i culture, ES-R1 cells were maintained in N2B27+Lif medium (1:1 Neurobasal medium and Advanced DMEM/F-12, 1% N-2 supplement, 2% B-27 supplement, 0.05% Bovine albumin fraction V, 1% GlutaMAX, 1% penicillin-streptomycin, 0.1 mM 2-mercaptoethanol, 10 ng/mL Lif) supplemented with 1 μm PD0325901 (Miltenyi Biotec #130-103-923) and 3 μm CHIR99021 (Miltenyi Biotec #130-103-926).
For retinoic acid differentiation assays, cells were seeded in 6-well plates in medium without Lif (serum medium for D1and D8, N2B27 medium for D18) and treated with 1 μM of Retinoic Acid (Sigma #R2625). Medium was refreshed every day for a total of 5 days of treatment. Cells were collected every 24 h for RNA extractions.
For 5-azacytidine experiments, cells were seeded in 6-well plates in serum+Lif medium and treated with 0.1 μM of 5-azacytidine (Abcam #ab142744). Medium was refreshed every day for a total of 5 days of treatment.
500 cells (D1 and D8 in serum+Lif medium; D18 in N2B27+Lif) were seeded in 6-well plates. After 6 days, cells were fixed with 4% paraformaldehyde for 5 min and washed twice with PBS.
Colonies were stained using Alkaline Phosphatase Blue Membrane Solution Kit (Sigma #AB0300) for 15 min in the dark. Wells were washed once with PBS and left to dry. Plates were scanned and colonies were counted using ImageJ.
On Day 1: first round. 500 000 ES R1 cells were plated per well well of a gelatin-coated 6-well plate in 2 ml of serum+Lif medium, supplemented with 0.1 μM of TAK-981. On Day 2, medium was replaced (aspirated) to refresh treatment (2 mL of Serum+Lif medium, supplemented with 0.1 μM of TAK-981 were added). After 48 h of treatment, on Day 3, the medium was aspirated and wells were rinsed twice with PBS then cells were allowed to recover in 2 ml of added serum+Lif. 6 days after the end of the first round, cells were similarly counted and plated for a 2nd round of TAK-981 (for example starting on Day 9 from the start of first round). On Day 9, 500 000 ES R1 cells were seeded per well on a gelatin-coated 6-well plate in 2 mL of Serum+Lif medium, supplemented with 0.1 μM of TAK-981 On day 10, the medium was aspirated and 2 ml of serum+Lif medium were added, supplemented with 0.1 μM of TAK-981 After 48 h of treatment (on Day 11), the medium was aspirated and wells were rinsed twice with PBS then cells were allowed to recover in 2 ml of N2B27+Lif medium that were added. Culture was carried out in N2B27+Lif medium. 3 to 5 days later (Day 14 to 16), cells form three-dimensional adherent spheroids, which can be maintained in culture or frozen for subsequent use (cell stocks in ES cell qualified FBS with 10% DMSO).
Cell surface markers specific to each spheroid cell type were extracted from the list of scRNA-seq cluster markers. The markers chosen for XEN-L and EPI-L cells were previously validatedO58.
Spheroids were briefly dissociated with StemPro Accutase (Gibco #A111-05-01) and cells were resuspended in PBS with 3% ES cell qualified FBS. Cells were incubated for 30 min at 4° C. with the following antibodies: Cd31(Pecam1)-FITC (1:100, Invitrogen #11-0311-81), Pdgfra(Cd140)-PE (1:100, Invitrogen #12-1401-81), Cd24a-APCeFluor780 (1:100, Invitrogen #47-0242-82). Cells were washed twice with PBS-3% ES cell qualified FBS then resuspended in PBS-3% ES cell qualified FBS. Propidium iodide (1 ug/mL, Invitrogen #P3566) was added to cell suspension before transferring sample to a cell strainer cap tube. Cells were analyzed on a BD FACSAria Ill Cell Sorter (BD Biosciences). Cell fractions were collected in PBS-3% ES cell qualified FBS then divided for RNA extraction and resuspension in N2B27+Lif medium for re-plating.
1 mL of anti-adherence rinsing solution (StemCell Technologies #07010) was added to each well of an AggreWell™800 plate (StemCell Technologies #34815). Plate was centrifuged for 5 min at 2,000 rpm then incubated 30 min at room temperature in a tissue culture hood. Wells were washed twice with 2 mL of PBS, then 500 μL of N2B27+Lif medium were added and plate was stored in a humidified incubator (37° C., 5% CO2) until use.
Spheroids were briefly dissociated with Trypsin-EDTA and 30,000 cells in 1 mL of N2B27+Lif were seeded in each well (˜100 cells per microwell). Plate was incubated (37° C., 5% CO2) for 3 days to obtain gastruloids.
For BMP inhibitor experiments, 500 nM of BMP inhibitor II DMH1 (Sigma #203646) was added at seeding and gastruloids were collected after 3 days for RNA extraction.
The molds to fabricate the chips were designed using Fusion 360 (Autodesk). The molds were patterned with 81 traps on the top of the culture chamber (
Pluripotent Stem Cell Loading and Manipulation within Immobilized Droplets
An Upchurch cross-junction (PEEK, low pressure, 1/16 compression size) was used to form 7 μL plugs flowed at 1,000 μL/mL using syringe pumps (neMESYS, Cetoni) and containing 120-300 pluripotent stem cells (PSCs) in their medium. The aqueous plugs were separated by 6 μL plugs of fluorogenic oil (FC-40, 3M) containing a fluorogenic surfactant (RAN biotechnologies) at a concentration of 0.5% v/v, and were also flowed at 1,000 μL/min. The chips were placed at an angle of 45° from the horizontal to allow gravity to act as a driving force for droplet motion. The drops were then spontaneously captured by capillarity in the bottom part of the traps, thus preventing other drops from being anchored in the same traps at this stage. Next, the drops spontaneously moved by gravity to the top part of the traps after 3-5 minutes, leaving empty the bottom part of the traps (the capillary anchoring zone). The chips were then placed in a humidified incubator (37° C., 5% CO2) to allow PSC culture for long time periods.
The performance of the droplet-microfluidic platform to promote PSC aggregation and expansion, and maintain expression of pluripotency markers was compared to standard 96-well plates. Briefly, about 300 mES-D3 were encapsulated into drops containing ESLIF medium, while the same cell number was seeded into 96-well plates in 100 μL of ESLIF medium per well. The kinetics of cell aggregation and proliferation were monitored by imaging. The level of expression of pluripotency marker Ssea1 was quantified by flow cytometry, using an LSR-Fortessa (BD Biosciences), and by labelling the cells with mouse AlexaFluor647-conjugated anti-Ssea1 antibody (1:100, BD Biosciences #560120).
The level of expression of pluripotency marker Oct4 was analyzed by imaging after methanol fixation and in situ immunolabelling using a mouse anti-Oct4 antibody (1:100, Millipore #MAB 4419), which was revealed using an AlexaFluor488 conjugated goat anti-mouse IgG1 (1:100, Invitrogen #A21121).
Spheroids were briefly dissociated with Trypsin-EDTA and a suspension of 168,000 cells in 10 mL of N2B27+Lif was prepared (˜120 cells per 7 μL droplet). Cells were loaded into the droplet-microfluidic device as described above and incubated for 5 days (37° C., 5% CO2) to obtain late gastruloids.
Structures were recovered from the droplet-microfluidic device after 4 days by flipping the chip at a 90° angle while flushing pure FC-40. The oil was separated from the aqueous phase containing the gastruloids by filtration on a PTFE membrane (Thermo-Fisher #F2517-9). 1-4 gastruloids were seeded in each well flat-bottom of low adhesion 96-well plates (Corning #3474) in 100 μL of N2B27+Lif medium containing 20% Matrigel (Corning #354234). Plates were incubated for 2 to 3 days (37° C., 5% CO2) to promote elongation of the embryo-like structures.
Spheroids were seeded in 8-well chamber slides (Ibidi #80826) at a density of 40,000 cells /300 μL. 48 h later, cells were fixed in 4% paraformaldehyde for 8 min, permeabilized in 0.2% Triton-PBS for 20 min and incubated in blocking buffer (10% BSA, 5% serum, 0.1% Triton-PBS) for 2 h at room temperature. For gastruloids, the structures were collected from AggreWells and fixed in 4% paraformaldehyde for 15 min. Then, the structures were permeabilized in 0.5% Triton-PBS for 20 min and incubated in blocking buffer (10% BSA, 5% serum, 0.1% Triton-PBS) for 3 h at room temperature. Primary antibodies were diluted in 1% BSA, 0.1% Triton-PBS and incubated overnight at 4° C. with the spheroids or the gastruloids. After 3 washes of 10 min in PBS, the structures were incubated with the secondary antibodies diluted at 1:400 for at least 1 h at room temperature then washed with PBS 3 times for 10 min. To immunolabel the late gastruloids and the embryo-like structures, the samples were first fixed with 4% paraformaldehyde for 2 hours at 4° C. The structures were then incubated overnight at 4° C. in PBSFT (5% FBS and 0.5% Triton-X100 in PBS). The primary antibodies were diluted in PBSFT and incubated with the samples overnight at 4° C. on an orbital rocker. After 3 washes with PBSFT, the samples were incubated overnight with a solution of 1:100 diluted secondary conjugated antibody containing 0.2 mM DAPI (Thermo-Fisher #R37606) at 4° C. on an orbital rocker. After washing with PBS, the samples were cleared using RapiClear 1.52 (Sunjin lab), following the manufacturer's instructions. The specificity of the primary antibodies was verified by incubating the samples with the secondary antibody alone. Under these conditions, an absence of fluorescent signal validated the specificity of the primary antibodies.
The antibodies used were rat anti-Nanog (1:300, eBioscience #14-5761-80), goat anti-Sox17 (1:100, R&D Systems #AF1924), rabbit anti-Pou3f1 (1:100, Sigma #HPA073824), goat anti-T (1:100, R&D Systems #AF2085) or rabbit anti-T (1:100, Abcam #ab209655), mouse anti-Pax6 (1:100, Abcam #ab78545), rabbit anti-Foxa2 (1:100, Cell Signaling #D56D6), mouse anti-Sox2 (1:100, Millipore #17-656), mouse anti-Tuj1 (1:100, Biolegend #801201), rabbit anti-Pax2 (1:100, Invitrogen #71-600), mouse anti-Map2 (1:100, Sigma-Aldrich #M4403), rabbit anti-Sox10 (1:100, Abcam #ab264405), AlexaFluor488 donkey anti-rat (Invitrogen #A21208), AlexaFluor546 donkey anti-goat (Invitrogen #A11056), AlexaFluor647 donkey anti-rabbit (Invitrogen #A31573), AlexaFluor488 goat-anti-mouse (Invitrogen #Al1001).
Gastruloids were collected 4 days after cell seeding in AggreWells and fixed for 7 h in 4% paraformaldehyde at 4° C. before dehydration in methanol. No proteinase K incubation was performed after rehydration. Embryo-like structures were collected 2 days after Matrigel embedding and fixed overnight in 4% paraformaldehyde at 4° C. before dehydration in methanol. Structures were incubated for 10 min with proteinase K (10 μg/mL) after rehydration. In situ whole mount HCR V3 was performed as previously described31 using reagents from Molecular Instruments. Briefly, each condition (up to 100 gastruloids or 20 embryo-like structures) was incubated in 1 mL of probe hybridization buffer for 5 min at room temperature and 30 min at 37° C. before incubation with 2 μmol of each probe in 500 μL of probe hybridization buffer overnight at 37° C. The next day, samples were washed 4×15 min with 1 mL probe wash buffer at 37° C., and 2×5 min with 1 mL 5×SSC-Tween at room temperature, then incubated in 1 mL amplification buffer for 5 min at room temperature. A mixture of 30 μmol of each hairpin (individually snap cooled beforehand) in 500 μL of amplification buffer was added to samples for an overnight incubation at room temperature in the dark. The next day, samples were washed 2×5 min, 2×30 min, 1×5 min with 1 mL 5×SSC-Tween at room temperature in the dark then stored at 4° C. before imaging. Accession numbers for HCR probes used were Nanog (NM_001289828.1, hairpin B1), T (NM_009309.2, hairpin B3), En1 (NM_010133.2 hairpin B4), Uncx (NM_013702.3, hairpin B1). Hairpins B1 were labeled with AlexaFluor488 or AlexaFluor546, hairpin B3 with AlexaFluor647 and hairpin B4 with AlexaFluor488 or AlexaFluor647.
The images were acquired using a motorized microscope (Ti or Ti 2, Eclipse, Nikon), equipped with a CMOS (complementary metal-oxide semiconductor) camera (ORCA-Flash4.0, Hamamatsu). Widefield imaging was performed by illuminating the samples with a fluorescence light-emitting diode source (Spectra X, Lumencor), while for spinning disc confocal imaging the samples were illuminated with lasers (W1, Yokogawa). The images were taken with a 10× objective with a 4-mm working distance (extra-long working distance) and a 0.45 numerical aperture (NA) (Plan Apo λ, Nikon).
For widefield live imaging, the samples were imaged using a Muvicyte (Perkin-Elmer) equipped with a 10× objective with a 10-mm working distance and 0.30 NA (UPIanFL N, Olympus), which was placed in a humidified incubator (37° C., 5% CO2). Images were acquired in brightfield every 30 min for the embryo-like structures in Matrigel. For the fluorescent reporter cell line Sox1::eGFP-T::mCherry, cells were cultured in phenol red-free N2B27+Uf medium and images were acquired every 3 hours.
The brightfield and fluorescent images were analyzed with a Python custom image analysis algorithm. Briefly, the aggregates were first detected from the brightfield images by edges detection. They were then centered and aligned along their major axis, which enabled to measure their major (a) and minor (b) axis length. The eccentricity was calculated as follows:
The fluorescent images were segmented using an automatically calculated threshold (Otsu's method). Then, the segments corresponding to gastruloids were oriented along their major axis, according to their red fluorescent signal (i.e. mCherry, TRITC). To quantify the time evolution of the structural organization within Sox1::eGFP-T::mCherry fluorescent reporter gastruloids, the distance of the maximum intensity of the mCherry and eGPF signals from the structure's center was calculated for every time point. In addition, the area of the mCherry and eGFP signals was measured for every time point.
For immunofluorescence and in situ HCR samples, the length of the major or minor axis was normalized for each gastruloid. Then, the images were segmented along the selected axis into a specific number of bins (ranging from −0.5 to 0.5, with 0 being the center of the gastruloid), for which the average fluorescent signal of each channel was measured.
Cells were dissociated with Trypsin-EDTA and resuspended in PBS. Propidium iodide (1 ug/mL, Invitrogen #P3566) and Calcein AM (1.5 ug/mL, Invitrogen #C3100MP) were added to cell suspension before transferring sample to a cell strainer cap tube. Cells were sorted into 384-well cell capture plates using a BD FACSAria Ill Cell Sorter (BD Biosciences) to collect live cells and sort only singlets. Plates were snap frozen on dry ice and stored at −80° C. until further processing. All single cell libraries were prepared with the same conditions and reagents using the MARS-seq protocol as previously described59. Briefly, a Bravo Automated Liquid Handling Platform (Agilent) was used to reverse transcribe (Invitrogen #18080085) mRNA into cDNA with an oligonucleotide containing both the unique molecule identifiers (UMIs) and cell barcodes. Unused oligonucleotides were removed by Exonuclease I (New England Biolabs #M0293S) treatment. cDNAs were pooled (each pool containing half of a 384-well plate) for second strand synthesis (New England Biolabs #E6111S) and in vitro transcription amplification (New England Biolabs #E2040S). DNA template was removed (Invitrogen #AM2238) before fragmenting (Invitrogen #AM8740) and ligating (New England Biolabs #M0204S) resulting RNA to an oligo containing the pool barcode and Illumina sequences. Finally, RNA was reverse transcribed (Agilent Technologies #600107) and libraries were amplified (Roche #7958935001). Libraries were quantified with a Qubit 2.0 (Invitrogen) and their size distribution was determined by a 4200 TapeStation System (Agilent Technologies). Finally, libraries were pooled at equimolar concentration and sequenced on an Illumina NextSeq500, in 8 sequencing runs, using high-output 75 cycles v2.5 kits (Illumina #20024906).
The mouse genome GRCm38.p6 (mm10) with the gencode annotation M23 was used for all sequencing analyses (https://www.gencodegenes.org/mouse/release M23.html).
The MARS-seq2.0 pipeline60 was used to produce count tables. The Seurat 4R package61 was used for normalization, dimension reduction and clustering. A manual iterative strategy was used to exclude cell libraries with low complexities. Briefly, all libraries (cells and empty control wells) in the count matrix were run through a standard Seurat workflow from count data to cluster computation (50 PCA dimensions to generate the neighbors' graph and UMAP computation). Empty wells and poor-quality cells usually clustered together and manual inspection allowed removal of clusters with low UMIs (inferior in mean˜1000 UMIs). This process was repeated until no low UMIs cluster remained. Cells with mitochondrial gene expression fractions greater than 2.5% were also excluded. Batch effects due to sequencing runs performed on different days were removed using the Harmony package62 in Seurat. Cluster markers were computed with the ‘FindAllMarkers’ Seurat function using the default parameters (except for the only.pos argument set to True, to only list genes upregulated in each cluster). Markers were considered significant if their adjusted p-value was inferior to 0.05. The cell cycle score was computed with the ‘CellCyclingScoring’ Seurat function using the provided gene list.
Comparison Between scRNA-Seq Clusters and In Vivo Datasets
For the D18 spheroid clusters comparison to in vivo data, the ‘FindMarkers’ Seurat function was used to compute genes differentially expressed between the XEN-L (#2) and EPI-L (#3) clusters. The list of genes upregulated in each cluster was compared to the lists of differentially expressed genes between the epiblast and the primitive endoderm/visceral endoderm at E4.5, E5.5, E6.527. For the AggreWell gastruloids, droplet-microfluidic device gastruloids and Matrigel embryo-like structures, the lists of cluster markers computed with the ‘FindAllMarkers’ Seurat function were compared to the markers identified for the different embryonic cell types defined in previously published mouse embryo scRNA-seq datasets28,35. Common genes, with a log2-transformed fold change superior to 1.01 and an adjusted p-value inferior to 0.01, were found and significance was assigned using a binomial test as previously described10.
DNA was extracted and purified from 2 million cells for each condition with the Quick-DNA Midiprep Plus Kit (Zymo Research D4075) following manufacturer's instructions. DNA was quantified with a NanoDrop ND-1000 (ThermoFisher Scientific). The NEBNext Enzymatic Methyl-seq Kit (New England Biolabs #E7120S) was used to prepare libraries for detection of 5-mC and 5-hmC. 200 ng of DNA from each sample were sheared to 275 bp fragments with an E220 Focused-ultrasonicator (Covaris) with the following settings: Duty Factor, 10%—Peak Incident Power, 175 W—Cycles per burst, 200—Duration, 100 sec. Fragment size was validated by a 4200 TapeStation System (Agilent Technologies). The NEBNext Enzymatic Methyl-seq Kit workflow was then followed, using the sodium hydroxide option for the denaturation step. The size distribution and concentration of the libraries was determined by TapeStation. The libraries were sequenced on an Illumina HiSeq4000 sequencer as paired-end 100 base reads following Illumina's instructions. Image analysis and base calling were performed using RTA 2.7.3 and bcl2fastq 2.17.1.14.
Methyl-seq data were processed with the Bismark pipeline62 using bowtie2 aligner64 with the default parameters. Biological triplicates were merged and CG sites with at least 5 reads were kept for downstream analyses. Methylated and unmethylated CG sites were counted within predetermined windows (bin or interval) and a binomial test was used to compare different timepoints or regions. ESC super-enhancers genome coordinates were taken from Whyte et al65. The liftOver webtool from the UCSC website (https://aenome.ucsc.edu/cai-bin/haLiftOver) was used to convert the mm9 track bed file to a mm10 bed file. The chromHMM genome annotation for ESCs produced by Pintacuda et al66 was also used (https://aithub.com/auifenawei/ChromHMM mESC mm10).
Cells at D1, D3, D8 and D10 were fixed for 10 min at room temperature in culture medium with 1% formaldehyde (Thermo Scientific #28908). Formaldehyde was then quenched with glycine (125 mM final). Cells were washed in ice cold PBS. The extracted chromatin was sonicated with a Bioruptor Pico (Diagenode) until chromatin fragments reached a size of 200-400 base pairs (30 sec ON, 30 sec OFF, 6 cycles), as assayed by electrophoresis through agarose gels. Immunoprecipitation, reversal of cross-linking and DNA purification were performed using ChIP-IT kit (Active Motif #53040). Polyclonal antibodies against SUMO1 (Abcam #ab32058), H3K4me3 (Active Motif #39159), H3K9me3 (Abcam #ab8898), H3K27me3 (Millipore #07-449) were used for ChIP-seq. For local ChIP experiments, a similar approach was performed using the following antibodies: SUMO2 (Abcam #ab3742), Zfp57 (Abcam #ab45341), Kap1 (Abcam #ab10483), Setdb1 (Proteintech #11231-1-AP), H3K9me3(Abcam #ab8898) and IgG (Cell Signaling #2729S).
50 ng of spike-in chromatin (Active Motif #53083) and 2 pg of spike-in antibody (Active Motif #61686) were added to normalize the signal between ChIP-seq experimental samples.
ChIP-seq libraries were prepared using Microplex Library Preparation kit V2 (Diagenode #C05010014) following the manufacturer's protocol (V2 02.15) with some modifications. Briefly, in the first step, 10 ng of double-stranded ChIP enriched DNA or input DNA was repaired to yield molecules with blunt ends. In the next step, stem-loop adaptors with blocked 5′ ends were ligated to the 5′end of the genomic DNA, leaving a nick at the 3′ end. In the third step, the 3′ends of the genomic DNA were extended to complete library synthesis and Illumina-compatible indexes were added through a high-fidelity amplification. In an additional step, the libraries were size selected (200-400 bp) and cleaned-up using AMPure XP beads (Beckman Coulter #A63881). Prior to analyses, DNA libraries were checked for quality and quantified using a 2100 Bioanalyzer (Agilent). The libraries were sequenced on an Illumina HiSeq4000 sequencer as paired-end 100 base reads following Illumina's instructions. Image analysis and base calling were performed using RTA 2.7.3 and bcl2fastq 2.17.1.14.
Libraries were aligned using bowtie264 with default parameters on mouse and fly genomes together. All alignments were filtered on MAPQ (mapping quality value) 30 with SAMtools67. Libraries were deduplicated with the Picard toolkites. The number of reads mapped on the fly genome was used as a spike-in value to downsample libraries as previously described69. Peak calling was performed with MACS270 with default parameters.
For the SUMO1 ChIP-seq data, low coverage peaks were filtered out. The pileup values were extracted from the MACS2 output, transformed using log10 and scaled. Peaks with a scaled log10 value inferior to −0.5 were filtered out from each replicate. This corresponded approximately to the 33% quantile (−0.52, −0.53, −0.48, −0.55, for D1 rep1, D1 rep2, D8 rep1, D8 rep2, respectively).
An irreproducible discovery rate (IDR)71 of 0.1 was used to filter out irreproducible peaks. For each histone mark or SUMO1 ChIP-seq dataset, the IDR validated peaks from all time points were merged using the bedtools merge function72.
A differential analysis was performed for the SUMO1 ChIP-seq data by counting the number of reads for each peak in each downsampled replicate with the featureCounts program73. The produced matrix was analyzed with the DESeq2R package74, using a size factor of 1 for the 4 libraries (2 rep D1, 2 rep D8). Changes of SUMO1 levels between D1 and D8 were considered significant if the adjusted p-value was inferior to 0.05.
For motif enrichment analysis, a 400 bp window centered on the local maximum coverage for each peak was first identified. The MEME-ChIP webtool75 was used with default parameters. H3K4me3 and H3K27me3 ChIP-seq data generated in this study were used to classify the transcription start sites (TSSs). TSSs were classified as “inactive” in the absence of both peaks, “active” when marked only by H3K4me3, “repressed” when marked only by H3K27me3 and “bivalent” when having both H3K4me3 and H3K27me3. The class of TSSs was attributed for SUMO peaks overlapping the 1kb neighborhood centered in any TSS. SUMO peaks were annotated with the following priority: TSS, exon, intron, intergenic with respect to the UCSC mm10 transcript annotations.
The EGSEA R package76 was used for gene list enrichment with Gene Ontology term (GO term), pathways (KEGG, Biocarta) or curated gene list (mSigDB) with the egsea.ora function (Over-representation Analysis).
Total RNA was purified by Trizol extraction and RNA was analyzed on a BioAnalyzer Nano chip (Agilent). If the RNA integrity number was superior to 8, samples were used for subsequent analyses. RNA concentration was quantified with a Qubit (Invitrogen). Total RNA-seq libraries were generated from 500 ng of total RNA using TruSeq Stranded Total RNA Library Prep Gold kit and TruSeq RNA Single Indexes kits A and B (Illumina), according to manufacturers instructions. Briefly, cytoplasmic and mitochondrial ribosomal RNA (rRNA) were removed using biotinylated, target-specific oligos combined with Ribo-Zero rRNA removal beads. Following purification, the depleted RNA was fragmented into small pieces using divalent cations at 94° C. for 2 minutes. Cleaved RNA fragments were then copied into first strand cDNA using reverse transcriptase and random primers followed by second strand cDNA synthesis using DNA Polymerase I and RNase H. Strand specificity was achieved by replacing dTTP with dUTP during second strand synthesis. The double stranded cDNA fragments were blunted using T4 DNA polymerase, Klenow DNA polymerase and T4 PNK. A single ‘A’ nucleotide was added to the 3′ ends of the blunt DNA fragments using a Kenow fragment (3′ to 5′exo minus) enzyme. The cDNA fragments were ligated to double stranded adapters using T4 DNA Ligase. The ligated products were enriched by PCR amplification (30 sec at 98° C.; [10 sec at 98° C., 30 sec at 60° C., 30 sec at 72° C.]×12 cycles; 5 min at 72° C.). Surplus PCR primers were further removed by purification using AMPure XP beads (Beckman Coulter #A63881) and the final cDNA libraries were checked for quality and quantified using capillary electrophoresis. The libraries were sequenced on an Illumina HiSeq4000 sequencer as paired-end 50 base reads following Illumina's instructions. Image analysis and base calling were performed using RTA 2.7.3 and bcl2fastq 2.17.1.14.
Processing bulk RNA-seq data FastQC (Version 0.11.2) was run using the following arguments—nogroup—casava to produce base quality, base sequence content and duplicated reads. FastQ-Screen (Version 0.5.1) was run using the following arguments:—subset 10000000—aligner bowtie—bowtie′-p 2′×. In order to avoid PCR amplification biases in read quantification, duplicated reads were removed using the MarkDuplicates tool of Picard. The differential expression analysis of DESeq2 was applied on the filtered replicates”.
Cells were collected and directly lysed in Laemmli buffer (Bio-Rad #161-0747). Proteins were quantified using Pierce 660 nm Protein Assay (ThermoFisher Scientific #22662) according to manufacturer's instructions. Equal amounts of proteins were loaded on gels and good equilibration of the different samples was assessed by Ponceau staining after membrane transfer. Antibodies against SUMO1 (1:1000, Abcam #ab32058), Actin (1:4000, Sigma #A1978), SUMO2/3 (1:1000, Abcam #ab81371), Gapdh (1:1000, Cell Signaling #2118), Dnmt1 (1:1000, Abcam #ab13537), Dnmt3a (1:1000, Abcam #ab2850), Dnmt3b (1:1000, Abcam #ab2851), Tet2 (1:1000, Cell Signaling #36449S), Histone H3 (1:5000, Abcam #ab24834) were used according to standard protocols and suppliers' recommendations.
cDNA was generated with a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems #4368814) from 500 ng to 2 pg of total RNA purified by Trizol extraction. Quantitative real-time PCR analysis was performed with SYBR Green PCR master mix (Applied Biosystems #4309155) and the primer sets indicated in Supplementary Table 7 using cDNA or genomic DNA (local ChIP). Quantitative real-time PCR analysis was performed on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad) or a QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems).
Preparation of Gastruloids from hypoSUMOylated mouse Embryonic Stem Cells (mESCs)
We used ML-792, a highly selective inhibitor of the small ubiquitin-like modifier (SUMO) E1 enzymes, to decrease the global level of SUMOylation in mouse ESCs, and found that two rounds of 48 h treatments, followed by a medium switch, yielded large spheroid structures on adherent plates (
Recent studies demonstrated that combining ESCs, XENs and trophoblast stem cells (TSCs) generates Embryo-Like Structures (ELS) closely recapitulating gastrulation2,3. We thus hypothesized that crosstalk between spheroid cell types in specific culture conditions might mimic morphogenetic events akin to early embryogenesis. Transferring 100 spheroid cells to a non-adherent microwell (AggreWell) resulted in elongated structures after 3 days, with 80% efficacy (
Together, these results show that self-organized structures generated from spheroids largely recapitulate architecture typical of the post-implantation mouse embryo, and will henceforth be referred to as “gastruloids”.
Microfluidic systems have recently been used to improve multicellular self-organization in controlled environments13,31-33. To expand the developmental potential of gastruloids, we seeded 120 dissociated cells from D18 spheroids in a new custom-made droplet-microfluidics platform optimized for ESC culture (
To gain mechanistic insight into how transient hypoSUMOylations in ESCs generate 3 cell types, we performed scRNA-seq at D1, D3, D8 and D10 (
The increase of DNA methylation was more pronounced in ESC enhancer regions, and correlated with a decreased transcription of neighboring genes including Nanog, Esrrb and Tbx3 (
Collectively, these data suggest that sequential waves of hypoSUMOylation progressively increase DNA methylation at pluripotency-associated genes, leading to their repression and favoring the expression of genes involved in tissue and embryo development (cluster 5,
As DNA methylation increases from D1 to D8, we hypothesized that the SUMO landscape may be altered after recovery from hypoSUMOylation. ChIP-seq profiling of SUMO1 identified 31,312 peaks, 924 of which were increased, and 403 decreased, at D8 compared to D1 (
It is noted that when spheroids were prepared using TAK-981 as the SUMO E1 inhibitor they exhibited the same properties as those obtained with ML-792 treatment which are disclosed in the present examples:
Here, we describe a new strategy to mimic mouse embryo development in absence of exogenous morphogens, that relies on transient waves of hypoSUMOylation to generate, from sole ESCs, self-organized ELS with all three germ layers. Crosstalk between the spheroid cell types is sufficient to trigger a series of morphogenetic events characteristic of natural gastrulation and early organogenesis that enable the emergence of additional cell populations regionalized in complex structures. However, important cell types from various stages of development are missing, including PGCs and forebrain tissue. Future work is needed to optimize culture conditions, such as adding a WNT agonist or using rotating culture platforms, to improve embryo-like morphology4,48. Importantly, D18 spheroids are stable after freeze/thaw cycles, allowing generation of ELS in only 7 days with one culture medium. Our protocol is thus highly scalable and adaptable. The added value of the droplet-microfluidic platform in boosting lineage diversity requires further investigation to determine whether this system modifies the physicochemical microenvironment (e.g. pH gradient) to favor axial elongation of gastruloids similar to natural embryos49.
Brief suppression of SUMOylation both decreased the heterogeneous expression of Nanog and increased the global level of DNA methylation, consistent with events of the peri-implantation stage50,51. This could suggest that a physiological wave of hypoSUMOylation may occur at gastrulation to facilitate cell fate determination, as demonstrated at the 2C-stage24,25. Finally, adjusting this protocol for human ESCs may provide new insights into early stages of development and the role of SUMO as a barrier to cell fate change. Overall, our work lays foundations for exploring epigenetic drugs as tools to control the balance between cell fate robustness and lineage commitment, with the ultimate goal of reconstructing complex multicellular architecture.
Traumatic spinal cord injury (SCI) is a devastating condition that often leads to significant life-long functional impairments, increased death rates, and huge costs in social and financial terms for patients and their families. The estimated annual global incidence is 40 to 80 cases per million population, meaning that approximatively three million people live with SCI, with 250,000 new cases each year. Disabilities may include partial or complete loss of sensory function or motor control of arms, legs and/or body and affect bowel or bladder control, breathing, heart rate, and blood pressure. Thus, SCI may render a person dependent on caregivers and assistive technology is often required to facilitate mobility, communication and self-care. Depression, related to SCI, has a negative impact on improvements in functioning and overall health. Children with SCI are less likely than their peers to start school while adults with SCI face similar barriers to economic participation, with a global unemployment rate>60%. To date, the only available treatment options include surgical stabilization and decompression of the spinal cord, and rehabilitative care, whereas the only approved pharmacological approach is the administration of high-dosed methylprednizolone, despite serious concerns.
Although specialized medical and surgical care have reduced mortality, novel and effective therapies that would confer long-term functional improvement/recovery represent an unmet clinical need. Cell transplantation is among the most promising strategies to promote repair and several early phase clinical trials have shown its feasibility. Candidate cell types may exert neuroprotective and/or neurodegenerative roles. For example, neural stem cells engraftment provides cell replacement of lost neurons, astrocytes, oligodendrocytes and growth factor support; Schwann cells and their precursors can support axon regeneration and remyelination after injury and also produce a variety of growth factors, mesenchymal stem cells may play an immunomodulatory and neuroprotecting role. Evidently, the application of a single-dimensional approach has failed to lead to recovery and co-transplantation of different cell types has presented with significant added therapeutic value.
Here, the inventors propose to graft embryo-like structures obtained using the methods and device of the invention that contain all three embryonic germ layer lineages in a mouse model for SCI. the above reported data show that these structures have the potential of forming distinct spinal cord neuronal precursors, Schwann cell precursors as well as other important elements including cells of the vasculature. The designed approach is expected to present several advantages over current protocols for SCI therapy, by combining the ameliorating effects of multiple cell types and the positive association of growth factors released.
The inventors' main objective is to evaluate the therapeutic benefit of embryo-like structures transplantation in a mouse model of dorsal column crush. At early stages after transplantation, the survival, integration and migration of grafted cells should be determined by immunohistochemistry, followed by assessing motor function recovery and tissue repair at later stages. In addition, the cutting-edge strategy of single-nucleus transcriptome analysis of grafted structures and host spinal cord tissue to identify lineage commitment of the grafted cells and also determine paracrine factors with potential therapeutic value should then be used. Within this context evaluating whether and how the transplantation of the cellular structures developed may promote neural tissue repair and functional improvement in a mouse model of SCI, would allow reaching the ultimate goal of transposing this approach for translation purposes. The novel type of embryo-like structures of the invention comprises (embryoids) and/or can give rise (gastruloids) to a variety of cell populations essential for recovery after SCI, e.g., neural precursors, neurons (ectoderm), Schwann cells (neural crest), endothelial cells (mesoderm), etc. In addition, these structures are expected to secrete a unique ECM template as well as a broad range of soluble signaling molecules that may favor SCI recovery. Embryoids, when compared to gastruloids, contain a number of more mature cell types that have lost their full cell plasticity. Therefore, implanting gastruloids may be preferred since they have the potential to generate neural and endothelial lineages, albeit devoid of undesirable cell types such as cardiomyocytes or gut progenitors. The inventors hypothesize that the direct transplantation of mESC-derived gastruloids will provide various types of precursor cells capable of promoting regeneration after SCI. they anticipate that the lesioned CNS microenvironment will supply molecular cues to instruct maturation of the grafted gastruloids into essential cell types that will participate in the repair mechanisms both in terms of cell replacement and of sourcing growth promoting molecules. By leveraging the ameliorating effects of multiple cell types, growth factors, ECM molecules and tissue bridging potential, this approach thus represents an innovative combinatorial strategy expected to remedy some of the shortcomings of current protocols for SCI therapy.
In reference to
On the drawings, it can be seen that the microfluidic device comprises an annular rim 105 onto which the plate 103 is bounded.
The traps 102 are distributed on a plurality of parallel columns. Preferably, the columns of traps are arranged in a staggered pattern. The body 101 may be made of polymer such as polydimethylsiloxane (PDMS). The body 101 presents a parallelepiped shape and a thickness comprised from 0.8 to 1.2 mm, in particular equal to 1 mm.
The body comprises a first longitudinal axis L corresponding to the direction of fluid flow, a second transverse axis T and third axis corresponding to the thickness Z of the body.
Each trap 102 comprises a cavity, extending along an axis of revolution X100, the cavity being intended to house at least a droplet introduced in the microfluidic device 100. Each trap 102 comprises an opening 106 opening out in a channel 114. The channel 114 is formed by a recess in a bottom side 116 of the body 101.
Each trap may be substantially perpendicular to the top 117 and bottom 116 sides of the microfluidic device 100.
Each trap 102 comprises a first part 104 of the cavity arranged between the opening 116 and a second part 108 of said trap 102, along the axis of revolution X100. The first part 104 of the cavity presents a dimension d1 along the axis of revolution X100 (i.e. the height of the first part) at least five times smaller than a dimension d2 of the second part 108 of the cavity along the axis of revolution X100 (i.e. the height of the second part). The dimension dl of the first part 104 of the cavity is comprised from 1 to 1.4 mm, in particular equal to 1.2 mm. The dimension d2 of the second part 108 of the cavity is comprised from 2 to 3.5 mm, in particular equal to 3 mm.
The first part 104 of the cavity is advantageously delimited by an annular curved wall 110 having a curvature R1=0.5 mm. The annular wall 110 is convex with regard to the axis of revolution X100. The cross section of the first part 104 of the cavity in a transverse plane perpendicular to the axis of revolution X100 is circular. The curvature R1 of the annular wall 110 increases towards the opening 106.
The opening 106 is also circular and presents a diameter Ø1 comprised from 2 to 3 mm, in particular from 2.2 to 2.6 mm, in particular equal to 2.4 mm.
The second part 108 of the cavity is delimited by a cylindrical wall 112 presenting a hexagonal cross section in the transverse plane. The hexagonal cross section of the second part 108 of the cavity presents an inscribed circle of a diameter Ø2 comprised from 1 to 2 mm, in particular comprised from 1.1 to 1.3 mm, in particular equal to 1.2 mm.
The diameter Ø1 of the opening 106 is greater than the diameter Ø2 of the hexagonal cross section.
Each trap 102 may comprise a third part 118 arranged at an end of the trap 102 opposite to the opening 106. The third part 118 is delimited by concave wall 120 forming a dome.
In an embodiment, each trap presents a dimension h2 along the axis of revolution comprised from 2 to 6 mm, in particular from 3 to 5 mm, in particular equal to 4 mm. h2 corresponds to the total height of the trap, i.e. the first, the second and the optional third parts. The dimension h2 is determined such as to allow the contact between the first droplet and the second droplet which leads to the fusion of the droplets thus forming a larger droplet as will be shown in the detailed description.
The channel 114 extends in a plane parallel to the bottom side 116 of the body 101 according to a hexagonal shape and covers all the openings 106 of the traps 102. A dimension h1 of the channel according to the axis of revolution X100 (i.e. the height of the channel) is comprised from 0.5 to 2 mm, in particular equal to 1 mm.
The diameter Ø1 of the opening 106 of a trap is at least equal or two times greater than the dimension h1 of the channel. The channel 114 connects an inlet 122 to a plurality of outlets 124 of the microfluidic device 100. The inlet 122 is arranged at a first end on a top side 117 of the body 101 opposite to the bottom side 116 in the direction of the axis of revolution X100. The inlet 122 is fluidically connected to the channel 114 by a duct 123 which forms an angle δ, with respect to the bottom side 116, comprised from 30° to 60°, in particular equal to 45°. The opening of the duct 123 in the channel 114 is advantageously delimited by an annular curved wall having a curvature R2. The annular curved wall is convex with regard to the axis along the length of the duct. The cross section of the opening of duct 123 in a transverse plane perpendicular to the axis along the length of the duct is circular. The curvature R2 of the annular wall increases towards the opening in the channel 114.
The fluid flows from the inlet 122 through the channel 124 to the outlets 124. In the direction of fluid flow, the device comprises a first end 122A located at the inlet 122 and a second end 124A located at the outlets 124.
The outlets 124 open out on the top side 117 of the body 101 and are arranged at a second end of the top side 117 opposite to the first end along the length of the body 101. The outlets 124 are connected to the channel 114 through respective vertical ducts.
Besides, the channel 114 is provided with four guiding rails 126 arranged for uniformly distributing the droplets outputted from the duct 123 in the channel 114. Each rail 126 presents a first end arranged next to the opening of the duct 123 in the channel 114. Each rail 126 presents a second end arranged next to a column of traps. Each rail 126 is a groove in the top surface of the channel 114 presenting a depth h3 smaller than two times the dimension h1 of the channel 114 along the axis of revolution X100, in particular equal to 0.5 mm.
Advantageously, the microfluidic device 100 comprises 81 traps distributed along 9 columns. However, the microfluidic device 100 may comprise any number of traps from 2 to 100.
The distance from the axis of revolution X100 of two adjacent traps 102 is comprised from 5 to 10 mm, in particular from 7 to 9 mm, and in particular equal to 8 mm.
In a particular embodiment illustrated in
The microfluidic device of
The microfluidic device 100 may be fabricated by molding. The process of fabrication of the microfluidic device 100 may comprise the following steps:
The glass slide may be a 75×50 mm rectangular.
An example of use of the microfluidic device 100 is shown in
Consequently, the first part 104 of the cavity of a trap 102 traps a first droplet 202 by capillarity. In a following step S102, the first droplet 202 migrates to the second part 108 of the cavity by buoyancy after a given time.
Following step S102, a second liquid composition comprising second droplets may be introduced in the microfluidic device 100 in a step S103. Advantageously, during the introduction of the second droplets, the microfluidic device 100 is tilted at a second angle with respect to the horizontal axis, comprised from 25° and 35°, in particular equal to 25°. The microfluidic device is tilted such as the outlets of the microfluidic device are above the horizontal axis while the inlet of the microfluidic device is below the horizontal axis. Consequently, the first part 104 of the cavity of the same trap 102 traps a second droplet 204 by capillarity. The second angle helps controlling the gravity forces in order to favor a second drop trapping in the anchors of the first part 104 of the cavity by capillary forces.
The dimension h2 allows the contact from the first droplet 202 and the second droplet 204 which leads to the fusion of the droplets 202 and 204 and forms a larger droplet 206 as shown in step S104.
Each first droplet 202 is introduced as a plug of aqueous phase having a volume comprised from 5 μL and 10 μL, in particular equal to 7 μL. The first liquid composition comprises also plugs of a fluorogenic oil having a volume comprised from 5 μL and 10 μL, in particular equal to 6 μL. The plugs of fluorogenic oil separates the first droplets 202. The fluorogenic oil contains a fluorogenic surfactant at 0.5% of the total weight.
After the migration of the first droplet 202 in the second part 108 of the cavity, the microfluidic device 100 can be placed in an incubator set up at 37° C. and 5% of CO2 to allow cell culture.
The cross section of the second part 108 of the cavity promotes shaping the first droplet 202 in a spheroid shape.
The second droplets 204 are soluble molecules such as culture medium, dyes, or a biomaterial.
In some embodiments, before the introduction of the second liquid composition, an immiscible fluorocarbon oil without surfactant or containing PFO (Perfluoro-Octanol (PFO), which reduces the emulsion stability) at concentration of 20% may be flushed in the traps. The immiscible fluorocarbon oil allows the fusion of the two droplets 202 and 204.
The first liquid composition and/or the second liquid composition are introduced in the microfluidic device at a flow of 1000 μL/min.
The use of the microfluidic device has been illustrated in the experimental data reported on
In some embodiments, the first and the second droplets comprise distinct media and are used to provide hydrogel encapsulation of embryo-like structures. For illustration it is described that
More generally the drop/droplet manipulation according to the invention, and the use of the droplet manipulation device of the invention provides the following advantages and improvements over the art:
The purpose was to use the technique of droplet fusion as disclosed herein wherein the second droplet contains liquid Matrigel in order to encapsulate embryo-like structures (ELS) within a hydrogel.
The following protocol was performed.
After oil-to-medium phase exchange, at least three different aqueous solutions of various chemical compositions could be perfused on a single chip. For this purpose, one outlet (124a) was placed in front of the middle group of traps (3 lanes in the example), and two other inlets (122b and 122c) were placed symmetrically to two other outlets (124b and 124c,
According to the invention, Matrigel droplet fusion directly in the device to prepare ELS allows direct perfusion of fresh medium while preserving the Matrigel. As a consequence, the obtained structures can continue growing.
An alternative medium could be used for Matrigel embedding and perfusion:
Genes & Development 15, 66-78 (2001).
| Number | Date | Country | Kind |
|---|---|---|---|
| 22305110.3 | Jan 2022 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2022/070715 | 7/22/2022 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63224805 | Jul 2021 | US |
